Akorn (AKRX) 10-Q 16 May 16 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 06, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	AKORN INC
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		119,427,471
Amendment Flag	false
Entity Central Index Key	3,116
Entity Filer Category	Large Accelerated Filer
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 140,998	$ 346,266
Trade accounts receivable, net	172,183	150,621
Inventories, net	190,869	185,316
Available for sale security, current	4,901	5,941
Prepaid expenses and other current assets	21,069	19,988
TOTAL CURRENT ASSETS	530,020	708,132
PROPERTY, PLANT AND EQUIPMENT, NET	186,258	179,614
OTHER LONG-TERM ASSETS
Goodwill	284,716	284,710
Product licensing rights, net	638,858	653,628
Other intangibles, net	210,453	211,361
Deferred tax assets	4,381	4,207
Long-term investments	130	129
Other non-current assets	1,031	764
TOTAL OTHER LONG-TERM ASSETS	1,139,569	1,154,799
TOTAL ASSETS	1,855,847	2,042,545
CURRENT LIABILITIES
Trade accounts payable	45,929	46,019
Purchase consideration payable	4,974	4,967
Income taxes payable	13,247	23,670
Accrued royalties	13,724	19,378
Accrued compensation	16,156	15,866
Current maturities of long-term debt (net of current deferred financing costs)	42,857	52,779
Accrued administrative fees	31,399	37,094
Accrued expenses and other liabilities	26,287	31,603
TOTAL CURRENT LIABILITIES	194,573	231,376
LONG-TERM LIABILITIES:
Long-term debt (net of non-current deferred financing costs)	807,142	994,033
Deferred tax liability	180,610	188,808
Lease incentive obligations and other long-term liabilities	6,935	6,763
TOTAL LONG-TERM LIABILITIES	994,687	1,189,604
TOTAL LIABILITIES	1,189,260	1,420,980
SHAREHOLDERS’ EQUITY
Common stock, no par value – 150,000,000 shares authorized; 119,427,471 and 119,427,471 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively	461,580	458,659
Retained earnings	221,934	180,048
Accumulated other comprehensive loss	(16,927)	(17,142)
TOTAL SHAREHOLDERS’ EQUITY	666,587	621,565
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 1,855,847	$ 2,042,545

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common stock, no par value (in Dollars per share)
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	119,427,471	119,427,471
Common stock, outstanding	119,427,471	119,427,471

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenues	$ 268,347	$ 227,378
Cost of sales (exclusive of amortization of intangibles, included within operating expenses below)	105,330	97,215
GROSS PROFIT	163,017	130,163
Selling, general and administrative expenses	49,086	29,986
Acquisition-related costs	197	1,257
Research and development expenses	9,479	9,276
Amortization of intangible assets	16,518	16,377
Impairment of intangible assets	158	0
TOTAL OPERATING EXPENSES	75,438	56,896
OPERATING INCOME	87,579	73,267
Amortization of deferred financing costs	(6,311)	(996)
Interest expense, net	(11,518)	(13,480)
Bargain purchase gain	0	849
Other non-operating expense, net	(3,178)	(1,312)
INCOME BEFORE INCOME TAXES	66,572	58,328
Income tax provision	24,686	20,790
CONSOLIDATED NET INCOME	$ 41,886	$ 37,538
CONSOLIDATED NET INCOME PER SHARE
CONSOLIDATED NET INCOME, BASIC (in Dollars per share)	$ 0.35	$ 0.33
CONSOLIDATED NET INCOME, DILUTED (in Dollars per share)	$ 0.34	$ 0.31
SHARES USED IN COMPUTING NET INCOME PER SHARE
BASIC (in Shares)	119,516	113,352
DILUTED (in Shares)	125,621	125,377
COMPREHENSIVE INCOME
Consolidated net income	$ 41,886	$ 37,538
Unrealized holding gain (loss) on available-for-sale securities, net of tax of $386 and ($59) for the three month periods ended March 31, 2016 and 2015, respectively.	(654)	101
Foreign currency translation income (loss), net of tax of $(447) and ($1,034) for the three month periods ended March 31, 2016 and 2015, respectively.	869	2,008
COMPREHENSIVE INCOME	$ 42,101	$ 39,647

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Other Comprehensive Income (Loss), Tax
Unrealized holding gain (loss) on available-for-sale securities, tax	$ 386	$ (59)
Foreign currency translation income (loss), tax	$ (447)	$ (1,034)

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Shareholders' Equity (Unaudited) - 3 months ended Mar. 31, 2016 - USD ($) $ in Thousands	Total	Common Stock [Member]	Retained Earnings [Member]	Other Comprehensive (Loss) Income [Member]
BALANCES AT at Dec. 31, 2015	$ 621,565	$ 458,659	$ 180,048	$ (17,142)
BALANCES AT (in Shares) at Dec. 31, 2015	119,427,471	119,427,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Consolidated net income	$ 41,886		41,886
Compensation and share issuances related to restricted stock awards	872	$ 872
Stock-based compensation expense	2,049	2,049
Foreign currency translation gain (loss)	869			869
Unrealized holding gain on available-for-sale securities	(654)			(654)
BALANCES AT at Mar. 31, 2016	$ 666,587	$ 461,580	$ 221,934	$ (16,927)
BALANCES AT (in Shares) at Mar. 31, 2016	119,427,471	119,427,000

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
OPERATING ACTIVITIES:
Consolidated net income	$ 41,886	$ 37,538
Adjustments to reconcile consolidated net income to net cash provided by operating activities:
Depreciation and amortization	22,468	21,109
Amortization of debt financing costs	6,311	996
Impairment of intangible assets	158	0
Amortization of favorable contracts	0	18
Amortization of inventory step-up	0	4,682
Non-cash stock compensation expense	2,921	2,974
Non-cash interest expense	454	1,186
Gain from product divestiture	0	0
Deferred income taxes, net	(8,009)	(9,186)
Excess tax benefit from stock compensation	0	(29,944)
Non-cash gain on bargain purchase	0	(849)
Loss on extinguishment of debt	0	98
Loss on sale of AFS securities	0	146
Changes in operating assets and liabilities, net of acquisition:
Trade accounts receivable	(21,355)	384
Inventories, net	(5,928)	(14,559)
Prepaid expenses and other current assets	(1,190)	2,896
Trade accounts payable	(1,948)	7,916
Accrued expenses and other liabilities	(26,783)	19,861
NET CASH PROVIDED BY OPERATING ACTIVITIES	8,985	45,266
INVESTING ACTIVITIES:
Payments for acquisitions and equity investments, net of cash acquired	0	(24,637)
Proceeds from disposal of assets	0	2,358
Payments for other intangible assets	(1,000)	0
Purchases of property, plant and equipment	(9,918)	(7,088)
NET CASH USED IN INVESTING ACTIVITIES	(10,918)	(29,367)
FINANCING ACTIVITIES:
Proceeds under stock option and stock purchase plans	0	10,958
Debt financing costs	(3,571)	0
Proceeds under borrowings	0	0
Consideration paid	0	(1,500)
Debt repayment	(200,000)	(2,613)
Excess tax benefit from stock compensation	0	29,944
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	(203,571)	36,789
Effect of exchange rate changes on cash and cash equivalents	236	165
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(205,268)	52,853
Cash and cash equivalents at beginning of period	346,266	70,679
CASH AND CASH EQUIVALENTS AT END OF PERIOD	140,998	123,532
SUPPLEMENTAL DISCLOSURES:
Amount paid for interest	10,613	11,836
Amount paid for income taxes, net of refunds received	$ 43,075	$ 238

Business and Basis of Presentat

Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS AND BASIS OF PRESENTATION	BUSINESS AND BASIS OF PRESENTATION Business: Akorn, Inc., together with its wholly-owned subsidiaries (collectively “Akorn”, the “Company”, “we”, “our” or “us”) is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals and branded as well as private-label over-the-counter consumer health products and animal health pharmaceuticals. We are an industry leader in the development, manufacturing and marketing of specialized generic pharmaceutical products in alternative dosage forms. We specialize in difficult-to-manufacture sterile and non-sterile dosage forms including, but not limited to, ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. Akorn is a Louisiana corporation founded in 1971 in Abita Springs, Louisiana. In 1997, we relocated our corporate headquarters to the Chicago, Illinois area and currently maintain our principal corporate offices in Lake Forest, Illinois. We operate pharmaceutical manufacturing facilities in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland; and Paonta Sahib, Himachal Pradesh, India. We also operate a central distribution warehouse in Gurnee, Illinois and additional distribution facilities in Amityville, New York and Decatur, Illinois. Our research and development (“R&D”) centers are located in Vernon Hills, Illinois; Copiague, New York; and Warminster, Pennsylvania. We also have other corporate offices in Ann Arbor, Michigan and Gurgaon, Haryana, India. For further detail concerning our reportable segments please see Note 10 “ Segment Information.” Our common shares are traded on The NASDAQ Global Select Market under the ticker symbol AKRX. Basis of Presentation : The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and accordingly do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments of a normal and recurring nature considered necessary for a fair presentation have been included in these financial statements. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the condensed consolidated financial statements and footnotes for the year ended December 31, 2015 , included in the Company’s Annual Report on Form 10-K filed on May 10, 2016. The Company has considered the accounting and disclosure of events occurring after the balance sheet date of March 31, 2016 through the filing date of this Form 10-Q. Certain prior-period amounts have been reclassified to conform to current-period presentation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Consolidation: The accompanying condensed consolidated financial statements include the accounts of Akorn, Inc. and its wholly owned domestic and foreign subsidiaries. All inter-company transactions and balances have been eliminated in consolidation, and the financial statements of Akorn India Private Limited ("AIPL") and Akorn AG (formerly "Excelvision AG" or "Hettlingen") have been translated from Indian Rupees to U.S. Dollars and Swiss Francs to U.S. dollars, respectively based on the currency translation rates in effect during the period or as of the date of consolidation, as applicable. The Company has no involvement with variable interest entities. Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. Significant estimates and assumptions for the Company relate to the allowances for chargebacks, rebates, product returns, coupons, promotions and doubtful accounts, as well as the reserve for slow-moving and obsolete inventories, the carrying value and lives of intangible assets, the useful lives of fixed assets, the carrying value of deferred income tax assets and liabilities, the assumptions underlying share-based compensation, accrued but unreported employee benefit costs and assumptions underlying the accounting for business combinations. Revenue Recognition: Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the sales price is fixed or determinable, and collectability is reasonably assured. Revenue from product sales are recognized when title and risk of loss have passed to the customer. Provision for estimated chargebacks, rebates, discounts, managed care rebates, product returns and doubtful accounts is made at the time of sale and is analyzed and adjusted, if necessary, at each balance sheet date. Freight: The Company records amounts billed to customers for shipping and handling as revenue, and records shipping and handling expense related to product sales as cost of sales. Cash and Cash Equivalents: The Company considers all unrestricted, highly liquid investments with maturity of three months or less when acquired, to be cash and cash equivalents. Accounts Receivable: Trade accounts receivables are stated at their net realizable value. The nature of the Company’s business involves, in the ordinary course, significant judgments and estimates relating to chargebacks, coupon redemption, product returns, rebates, discounts given to customers and allowances for doubtful accounts. Depending on the products, the customers, the specific terms of national supply contracts and the particular arrangements with the Company’s wholesaler customers, certain rebates, chargebacks and other credits are recorded as deductions to the Company’s trade accounts receivable. Unless otherwise noted, the provisions and allowances for the following customer deductions are reflected in the accompanying condensed consolidated financial statements as reductions of revenues and trade accounts receivable, respectively. Chargebacks, Rebates, Discounts and Other Adjustments: The Company enters into contractual agreements with certain third parties such as retailers, hospitals, group-purchasing organizations ("GPOs") and managed care organizations to sell certain products at predetermined prices. Similarly, we maintain an allowance for rebates and discounts related to billbacks, wholesaler service fee for service contracts, GPO administrative fees, government programs, prompt payment and other adjustments with certain customers. Most of the parties have elected to have these contracts administered through wholesalers that buy the product from the Company and subsequently sell it to these third parties. When a wholesaler sells products to one of these third parties that are subject to a contractual price agreement, the difference between the price paid to the Company by the wholesaler and the price under the specific contract is charged back to the Company by the wholesaler. The Company tracks sales and submitted chargebacks by product number and contract for each wholesaler. Utilizing this information, the Company estimates a chargeback percentage for each product and records an allowance as a reduction to gross sales when the Company records its sale of the products. The Company reduces the chargeback allowance when a chargeback request from a wholesaler is processed. Actual chargebacks processed by the Company can vary materially from period to period based upon actual sales volume through the wholesalers. However, the Company’s provision for chargebacks is fully reserved for at the time when sales revenues are recognized. Management obtains certain wholesaler inventory reports to aid in analyzing the reasonableness of the chargeback allowance and which are additionally monitored to ensure that wholesaler inventory levels by product do not significantly exceed underlying customer demand. The Company assesses the reasonableness of its chargeback allowance by applying the product chargeback percentage based on a combination of historical activity and future price and mix expectations to the quantities of inventory on hand at the wholesaler per wholesaler inventory reports. In accordance with its accounting policy, the Company estimates the percentage amount of wholesaler inventory that will ultimately be sold to third parties that are subject to contractual price agreements based on a trend of such sales through wholesalers. The Company uses this percentage estimate until historical trends indicate that a revision should be made. On an ongoing basis, the Company evaluates its actual chargeback rate experience, and new trends are factored into its estimates each quarter as market conditions change. Similarly, the Company maintains an allowance for rebates related to contract and other programs with certain customers. Rebate percentages vary by product and by volume purchased by each eligible customer. The Company tracks sales by product number for each eligible customer and then applies the applicable rebate percentage, using both historical trends and actual experience to estimate its rebate allowance. The Company reduces gross sales and increases the rebate allowance by the estimated rebate amount when the Company sells its products to its rebate-eligible customers. The Company reduces the rebate allowance when it processes a customer request for a rebate. At each balance sheet date, the Company analyzes the allowance for rebates against actual rebates processed and makes necessary adjustments as appropriate. Actual rebates processed can vary materially from period to period. Other adjustments consist primarily of price adjustments, also known as “shelf-stock adjustments” and “price protections,” which are both credits issued to reflect increases or decreases in the invoice or contract prices of the Company’s products. In the case of a price decrease a credit is given for product remaining in customer’s inventories at the time of the price reduction. Contractual price protection results in a similar credit when the invoice or contract prices of the Company’s products increase, effectively allowing customers to purchase products at previous prices for a specified period of time. Amounts recorded for estimated shelf-stock adjustments and price protections are based upon specified terms with direct customers, estimated changes in market prices, and estimates of inventory held by customers. The Company regularly monitors these and other factors and evaluates the reserve as additional information becomes available. Other adjustments also include prompt payment discounts. Sales Returns: Certain of the Company’s products are sold with the customer having the right to return the product within specified periods and guidelines for a variety of reasons, including but not limited to, pending expiration dates. Provisions are made at the time of sale based upon tracked historical experience. Historical factors such as one-time events as well as pending new developments that would impact the expected level of returns are taken into account to determine the appropriate reserve estimate at each balance sheet date. As part of the evaluation of the balance required, the Company considers actual returns to date that are in process, the expected impact of any product recalls and the wholesaler’s inventory information to assess the magnitude of unconsumed product that may result in sales returns to the Company in the future. The sales returns level can be impacted by factors such as overall market demand and market competition and availability for substitute products which can increase or decrease the pull through for sales of the Company’s products and ultimately impact the level of sales returns. Actual returns experience and trends are factored into the Company’s estimates each quarter as market conditions change. Actual returns processed can vary materially from period to period. Allowance for Coupons, Promotions and Co-Pay discount cards: The Company issues coupons from time to time that are redeemable against certain of our Consumer Health products. Upon release of coupons into the market, the Company records an estimate of the dollar value of coupons expected to be redeemed. This estimate is based on historical experience and is adjusted as needed based on actual redemptions. In addition to couponing, from time to time the Company authorizes various retailers to run in-store promotional sales of its products. Upon receiving confirmation that a promotion was run, the Company accrues an estimate of the dollar amount expected to be owed back to the retailer. This estimate is trued up to actual upon receipt of the invoice from the retailer. Additionally, the Company provides consumer co-pay discount cards, administered through outside agents to provide discounted products when redeemed. Upon release of the cards into the market, the Company records an estimate of the dollar value of co-pay discounts expected to be utilized. This estimate is based on historical experience and is adjusted as needed based on actual usage. Doubtful Accounts: Provisions for doubtful accounts, which reflect trade receivable balances owed to the Company that are believed to be uncollectible, are recorded as a component of selling, general and administrative ("SG&A") expenses. In estimating the allowance for doubtful accounts, the Company considers its historical experience with collections and write-offs, the credit quality of its customers and any recent or anticipated changes thereto, and the outstanding balances and past due amounts from its customers. Note that in the ordinary course of business, and consistent with our peers, we may from time to time offer extended payment terms to our customers as an incentive for new product launches and in other circumstances in accordance with industry practices. These extended payment terms do not represent a significant risk to the collectability of accounts receivable as of the period-end and are evaluated in accordance with Accounting Standards Codification (ASC) 605 - Revenue Recognition as applicable. Accounts are considered past due when they remain uncollected beyond the due date specified in the applicable contract or on the applicable invoice, whichever is deemed to take precedence. Advertising and Promotional Allowances to Customers: The Company routinely sells its consumer health products to major retail drug chains. From time to time, the Company may arrange for these retailers to run in-store promotional sales of the Company’s products. The Company reserves an estimate of the dollar amount owed back to the retailer, recording this amount as a reduction to revenue at the later of the date on which the revenue is recognized or the date the sales incentive is offered. When the actual invoice for the sales promotion is received from the retailer, the Company adjusts its estimate accordingly. Advertising and promotional expenses paid to customers are expensed as incurred in accordance with ASC 605-50 - Customer Payments and Incentives . Inventories: Inventories are stated at the lower of cost (average cost method) or market. The Company maintains an allowance for slow-moving and obsolete inventory as well as inventory where the cost is in excess of its net realizable value. For finished goods inventory, the Company estimates the amount of inventory that may not be sold prior to its expiration or is slow moving based upon review of recent sales activity and wholesaler inventory information. The Company also analyzes its raw material and component inventory for slow moving items. The Company capitalizes inventory costs associated with its products prior to regulatory approval when, based on management judgment, future commercialization is considered probable and future economic benefit is expected to be realized. The Company assesses the regulatory approval process and where the product stands in relation to that approval process including any known constraints or impediments to approval. The Company also considers the shelf life of the product in relation to the product timeline for approval. Intangible Assets: Intangible assets consist primarily of goodwill and in-process research and development, which are carried at initial value and subject to evaluation for impairment, and product licensing costs, trademarks and other such costs, which are capitalized and amortized on a straight-line basis over their useful lives, normally ranging from one year to thirty years . The Company regularly assesses its intangible assets for impairment based on several factors, including estimated fair value and anticipated cash flows. If the Company incurs additional costs to renew or extend the life of an intangible asset, such costs are added to the remaining unamortized cost of the asset, if any, and the sum is amortized over the extended remaining life of the asset. Goodwill is tested for impairment annually or more frequently if changes in circumstances or the occurrence of events suggest that impairment may exist. The Company uses widely accepted valuation techniques to determine the fair value of its reporting units used in its annual goodwill impairment analysis. The Company’s valuation is primarily based on qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. The Company models the fair value of the reporting unit based on projected earnings and cash flows of the reporting unit. Property, Plant and Equipment: Property, plant and equipment is stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method in amounts considered sufficient to amortize the cost of the assets to operations over their estimated useful lives or capital lease terms. The amortization of assets under capital leases is included within depreciation expense. Net Income Per Common Share: Basic net income per common share is based upon weighted average common shares outstanding. Diluted net income per common share is based upon the weighted average number of common shares outstanding, including the dilutive effect, if any, of stock options and convertible securities using the treasury stock and if converted methods. Anti-dilutive shares are excluded from the computation of diluted net income per share. Income Taxes: Income taxes are accounted for under the asset and liability method. Deferred income tax assets and liabilities are recognized for the tax effects of temporary differences between the financial reporting and tax bases of assets and liabilities, and net operating loss and other tax credit carry-forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce the recognized deferred tax assets to the amount that is more likely than not to be realized. Fair Value of Financial Instruments: The Company applies ASC 820 - Fair Value Measurement , which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 - Fair Value Measurement defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 - Fair Value Measurement generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability, and are to be developed based on the best information available in the circumstances. The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below: - Level 1 —Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. The carrying value of the Company‘s cash and cash equivalents and the portion of the value of the Nicox S.A. ("Nicox") shares which are available to be traded on the exchange are considered Level 1 assets. - Level 2 —Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. - Level 3 —Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. The portion of the fair valuation of the available for sale investment held in shares of Nicox S.A. ("Nicox") subject to a lock-up provision is considered a Level 3 asset. The additional consideration payable as a result of the ECR divestiture and other insignificant contingent amounts are considered Level 3 liabilities. The following table summarizes the basis used to measure the fair values of the Company’s financial instruments (amounts in thousands): Fair Value Measurements at Reporting Date, Using: Description March 31, 2016 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash and cash equivalents $ 140,998 $ 140,998 $ — $ — Available-for-sale securities 4,901 4,010 — 891 Total assets $ 145,899 $ 145,008 $ — $ 891 Purchase consideration payable $ 4,974 $ — $ — $ 4,974 Total liabilities $ 4,974 $ — $ — $ 4,974 Description December 31, 2015 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash and cash equivalents $ 346,266 $ 346,266 $ — $ — Available-for-sale securities 5,941 4,843 1,098 Total assets $ 352,207 $ 351,109 $ — $ 1,098 Purchase consideration payable $ 4,967 $ — $ — $ 4,967 Total liabilities $ 4,967 $ — $ — $ 4,967 As of March 31, 2016 , the Company was carrying available for sale investments in shares of Nicox. These shares of Nicox were initially valued at $12.5 million discounted to reflect certain lockup provisions preventing immediate conversion of underlying shares received for the Company’s investment in an available for sale security, or an approximately $1.7 million unrealized gain from the original costs basis of $10.8 million . During the years ended December 31, 2015 and 2014 the Company sold $2.6 million and $ 0.6 million , respectively of the available-for-sale securities. In the three months ended March 31, 2016 the Company did not sell any additional shares and due to sustained declines in the underlying Nicox share value, recognized a $2.7 million unrealized loss of the remaining investment value to date. A portion of the remaining $4.9 million of securities are subject to certain lockup provisions and as such, the fair value of the cost basis investments is estimated using observable and unobservable inputs to discount for lack of marketability. The remaining purchase consideration payable is principally comprised of amounts owed relating to the ECR and Watson Laboratories, Inc. (“Watson”) divestitures, at fair value as determined based on the underlying contracts and the Company’s subjective evaluation of the additional consideration. Stock-Based Compensation: Stock-based compensation cost is estimated at grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. The Company uses the Black-Scholes model for estimating the grant date fair value of stock options. Determining the assumptions to be used in the model is highly subjective and requires judgment. The Company uses an expected volatility that is based on the historical volatility of its common stock. The expected life assumption is based on historical employee exercise patterns and employee post-vesting termination behavior. The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities of similar term in effect during the quarter in which the options were granted. The dividend yield reflects the Company’s historical experience as well as future expectations over the expected term of the option. The Company estimates forfeitures at the time of grant and revises the estimate in subsequent periods, as necessary, if actual forfeitures differ from initial estimates. Business Combinations: Business combinations are accounted for in accordance with ASC 805 - Business Combinations , using the acquisition method of accounting. The acquisition method of accounting requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill reflects the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received. Under the acquisition method of accounting, the Company will identify the acquirer and the closing date and apply applicable recognition principles and conditions. Acquisition-related costs are costs the Company incurs to effect a business combination. The Company accounts for acquisition-related costs as expenses in the periods in which the costs are incurred.

Stock Based Compensation

Stock Based Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK BASED COMPENSATION	STOCK BASED COMPENSATION At the Company’s 2014 Annual Meeting of Shareholders, which took place May 2, 2014, the Company’s shareholders approved the adoption of the Akorn, Inc. 2014 Stock Option Plan (the “2014 Plan”). The 2014 Plan reserves 7.5 million shares for issuance upon the grant of stock options, restricted share units, or various other instruments to directors, employers and consultants. The 2014 Plan replaced the 2003 Stock Option Plan (the “2003 Plan”), which expired on November 6, 2013, although previously granted awards remain outstanding under the 2003 Plan. The Company uses the single-award method for allocating compensation cost related to stock options to each period. The following table sets forth the components of the Company’s share based compensation expense for the three month periods ended March 31, 2016 and 2015 (in thousands): Three months ended March 31, 2016 2015 Stock options and employee stock purchase plan $ 2,049 $ 2,252 Restricted stock units 872 722 Total stock-based compensation expense $ 2,921 $ 2,974 The weighted-average assumptions used in estimating the grant date fair value of the stock options granted under the 2014 Plan during the three month periods ended March 31, 2016 , and 2015 , respectively along with the weighted-average grant date fair values, are set forth in the table below. Three Months Ended March 31, 2016 2015 Expected volatility 47% 42% Expected life (in years) 4.75 4.75 Risk-free interest rate 1.26% 1.56% Dividend yield — — Fair value per stock option $ 9.95 $ 18.21 Forfeiture rate 8% 8% The table below sets forth a summary of activity within the 2014 and 2003 Plans for the three months ended March 31, 2016 : Number of Options (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (in thousands) (1) Outstanding at December 31, 2015 4,757 $ 20.33 3.41 $ 80,868 Granted 911 24.14 Exercised — — Forfeited (77 ) 27.69 Outstanding at March 31, 2016 5,591 $ 20.83 3.78 $ 116,467 Exercisable at March 31, 2016 2,591 $ 12.31 1.39 $ 31,879 (1) May include value from potentially anti-dilutive options whose exercise price exceeds the closing stock price. The aggregate intrinsic value for stock options outstanding and exercisable is defined as the difference between the market value of the Company’s common stock as of the date indicated and the exercise price of the stock options. During the three months ended March 31, 2016 , no stock options were exercised. During the three months ended March 31, 2015 , approximately 2.2 million stock options were exercised resulting in cash payments to the Company of approximately $9.2 million . These option exercises generated tax-deductions of approximately $84.9 million . From time to time the Company grants restricted stock units to certain employees and members of its Board of Directors (“Directors”). Restricted stock units are valued at the closing market price of the Company’s common stock on the day of grant and the total value of the units are recognized as expense ratably over the vesting period of the grants. On May 2, 2014, the Company granted a total of 71,582 restricted share units to senior management which vest at 25% per year on the anniversary date of the grant ending May 2, 2018. Also on May 2, 2014, the Company modified approximately 2.3 million options to extend the option term of certain individuals in Senior Management. On September 5, 2014, the Company granted a total of 257,416 restricted share units to senior management and 8,034 shares to a Director to make the individuals who received extended option terms on May 2, 2014 whole given increased tax liabilities. The options each vest at 25% per year on the anniversary date of the grant ending September 5, 2018. The following is a summary of non-vested restricted stock activity: Number of Units (in thousands) Weighted Average Grant Date Fair Value Non-vested at December 31, 2015 253 $ 35.31 Granted — — Forfeited — $ — Vested (34) $ 36.47 Non-vested at March 31, 2016 219 $ 35.13

Accounts Receivable Allowances

Accounts Receivable Allowances	3 Months Ended
	Mar. 31, 2016
Receivables [Abstract]
ACCOUNTS RECEIVABLE ALLOWANCES	ACCOUNTS RECEIVABLE ALLOWANCES The nature of the Company’s business inherently involves, in the ordinary course, significant amounts and substantial volumes of transactions and estimates relating to allowances for product returns, chargebacks, rebates, doubtful accounts and discounts given to customers. This is a natural circumstance of the pharmaceutical industry and is not specific to the Company. Depending on the product, the customer, the specific terms of national supply contracts and the particular arrangements with the Company’s wholesaler customers, certain rebates, chargebacks and other credits are deducted from the Company’s accounts receivable. The process of claiming these deductions depends on wholesalers reporting to the Company the amount of deductions that were earned under the terms of the respective agreement with the customer (which in turn depends on the specific customer, each having its own pricing arrangement, which entitles it to a particular deduction). This process can lead to partial payments against outstanding invoices as the wholesalers take the claimed deductions at the time of payment. With the exception of the provision for doubtful accounts, which is reflected as part of selling, general and administrative expense, the provisions for the following customer reserves are reflected as a reduction of revenues in the accompanying condensed consolidated statements of comprehensive income. The ending reserve balances are included in trade accounts receivable, net in the Company’s condensed consolidated balance sheets. Net trade accounts receivable consists of the following (in thousands): March 31, December 31, Gross accounts receivable $ 472,665 $ 466,570 Less reserves for: Chargebacks and rebates (238,028 ) (254,440 ) Product returns (49,337 ) (48,333 ) Discounts and allowances (10,281 ) (10,079 ) Advertising and promotions (1,488 ) (1,518 ) Doubtful accounts (1,348 ) (1,579 ) Trade accounts receivable, net $ 172,183 $ 150,621 For the three month periods ended March 31, 2016 and 2015 , the Company recorded the following adjustments to gross sales (in thousands): Three Months Ended March 31, 2016 2015 Gross sales $ 593,392 $ 568,016 Less adjustments for: Chargebacks and rebates (293,434 ) (293,181 ) Product returns (4,286 ) (5,574 ) Discounts and allowances (11,954 ) (14,044 ) Administrative fees (14,290 ) (26,123 ) Advertising, promotions and others (1,081 ) (1,716 ) Revenues, net $ 268,347 $ 227,378

Inventories

Inventories	3 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES The components of inventories are as follows (in thousands): March 31, December 31, Finished goods $ 82,021 $ 76,512 Work in process 9,900 8,905 Raw materials and supplies 98,948 99,899 Inventories, net $ 190,869 $ 185,316 The Company maintains reserves and records provisions for slow-moving and obsolete inventory as well as inventory with a cost in excess of its net realizable value. Inventory at March 31, 2016 and December 31, 2015 was reported net of these reserves of $23.2 million and $21.5 million , respectively.

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment consist of the following (in thousands): March 31, December 31, Land and land improvements $ 17,661 $ 17,409 Buildings and leasehold improvements 86,780 85,767 Furniture and equipment 146,653 142,885 Sub-total 251,094 246,061 Accumulated depreciation (93,139 ) (87,086 ) Property, plant and equipment placed in service, net $ 157,955 $ 158,975 Construction in progress 28,303 20,639 Property, plant and equipment, net $ 186,258 $ 179,614 A portion of the Company’s property, plant and equipment is located outside the United States. At March 31, 2016 and December 31, 2015 , property, plant and equipment, net, with a net carrying value of $56.7 million and $52.6 million , respectively, was located outside the United States at the Company’s manufacturing facilities in India and Switzerland. The Company recorded depreciation expense of approximately $6.0 million and $5.0 million during the three month periods ended March 31, 2016 and 2015 , respectively.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill: The following table provides a summary of the activity in goodwill by segment for the three months ended March 31, 2016 (in thousands): Consumer Health Prescription Pharmaceuticals Total Balances at December 31, 2015 $ 16,717 $ 267,993 $ 284,710 Currency translation adjustments — 6 6 Acquisitions — — — Impairments — — — Dispositions — — — Balances at March 31, 2016 $ 16,717 $ 267,999 $ 284,716 Goodwill acquired prior to December 31, 2015 attributed to the Consumer Health segment was due to the Company’s acquisition of Hi-Tech in April 2014 and the acquisition of Advanced Vision Research, Inc. in May 2011, while Goodwill attributed to the Prescription Pharmaceuticals segment relates to the Company’s acquisition of VersaPharm in August 2014, Hi-Tech in April 2014 and selected assets of Kilitch Drugs (India) Limited (“KDIL”) in February 2012. Product Licensing Rights, In-Process Research and Development (“IPR&D”), and Other Intangible Assets: The following table sets forth information about the net book value of the Company’s other intangible assets as of March 31, 2016 and December 31, 2015, and the weighted average remaining amortization period as of March 31, 2016 and December 31, 2015 (dollar amounts in thousands): Gross Amount Accumulated Amortization Reclass-ifications Impairment Net Balance Wtd Avg Remaining Amortization Period (years) March 31, 2016 Product licensing rights $ 787,269 $ (148,211 ) $ — $ (200 ) $ 638,858 10.8 IPR&D 186,932 — — — 186,932 N/A - Indefinite lived Trademarks 16,000 (3,298 ) — — 12,702 18.1 Customer relationships 6,343 (3,721 ) — — 2,622 10.1 Other intangibles 11,235 (3,038 ) — — 8,197 6.4 Non-compete agreement 2,319 (2,319 ) — — — — $ 1,010,098 $ (160,587 ) $ — $ (200 ) $ 849,311 December 31, 2015 Product licensing rights $ 782,269 $ (132,642 ) $ 38,000 $ (34,000 ) $ 653,627 13.2 IPR&D 227,559 — (38,000 ) (2,627 ) 186,932 N/A - Indefinite lived Trademarks 16,000 (2,982 ) — — 13,018 21.8 Customer relationships 6,493 (3,716 ) — — 2,777 11.7 Other intangibles 11,235 (2,600 ) — — 8,635 7.9 Non-compete agreement 2,167 (2,167 ) — — — — $ 1,045,723 $ (144,107 ) $ — $ (36,627 ) $ 864,989 The Company recorded amortization expense of approximately $16.5 million and $16.4 million during the three month periods ended March 31, 2016 and 2015, respectively. The Company also recognized impairment of intangible assets in the three month period ended March 31, 2016 of $0.2 million related to one product licensing right which was net of an immaterial accumulated amortization at the impairment date.

Financing Arrangements

Financing Arrangements	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
FINANCING ARRANGEMENTS	FINANCING ARRANGEMENTS Incremental Term Loan Concurrent with the closing of its acquisition of VersaPharm, Akorn, Inc. and its wholly owned domestic subsidiaries (the “Akorn Loan Parties”) entered into a $445.0 million Incremental Facility Joinder Agreement (the “Incremental Term Loan Facility”) pursuant to a Loan Agreement (the “Incremental Term Loan Agreement”) dated August 12, 2014 between the Akorn Loan Parties as borrowers, and JPMorgan Chase Bank, N.A. (“JPMorgan”), as lender and as administrative agent for certain other lenders. The proceeds received pursuant to the Incremental Term Loan Agreement were used to finance the VersaPharm Acquisition. The Incremental Term Loan Facility is secured by all of the assets of the Akorn Loan Parties, including springing control of the Company’s primary deposit account pursuant to a Deposit Account Control Agreement. The Incremental Term Loan Facility required quarterly principal repayment equal to 0.25% of the initial loan amount of $445.0 million beginning with the first full quarter following the closing date of the Incremental Term Loan Agreement, with a final payment of the remaining principal balance due at maturity seven years from the date of closing of the Existing Term Loan Agreement or April 16, 2021. The Company may prepay all or a portion of the remaining outstanding principal amount under the Incremental Term Loan Agreement at any time, or from time to time, subject to prior notice requirement to the lenders and payment of applicable fees. Prepayment of principal will be required should the Company incur any indebtedness not permitted under the Incremental Term Loan Agreement, or effect the sale, transfer or disposition of any property or asset, other than in the ordinary course of business. On February 16, 2016 the Company made a voluntary prepayment of its Incremental Term Loan facility of $85.2 million which settled all future quarterly principal repayments as denoted above until the date of the closing of the Incremental Term Loan Agreement or April 16, 2021 although future voluntary principal repayments are permitted. Effected for the principal repayment, as of March 31, 2016 outstanding debt under the Incremental Term Loan Facility was $354.3 million and the Company was in full compliance with all applicable covenants which included customary limitations on indebtedness, distributions, liens, acquisitions, investments, and other activities. Prior to November 13, 2015 interest accrued based, at the Company’s election, on an adjusted prime/federal funds rate (“ABR Loan”) or an adjusted LIBOR (“Eurodollar Loan”) rate, plus a margin of 2.50% for ABR Loans, and 3.50% for Eurodollar Loans. Each such margin would decrease by 0.25% in the event the Company’s senior debt to EBITDA ratio for any quarter falls to 2.25 :1.00 or below. During an event of default, as defined in the Existing Term Loan Agreement, any interest rate would be increased by 2.00% per annum. Per the Existing Term Loan Agreement, the interest rate on LIBOR loans could not fall below 4.50% . On May 20, 2015 the Company modified the Incremental Term Loan Facility with JPMorgan and certain other lenders to remedy certain covenant defaults related to the FY 2014 financial restatement by incurring nominal charges affected through a temporary interest rate increase and an upfront payment. On November 13, 2015 the Company again modified the Incremental Term Loan Facility with JPMorgan and certain other lenders to remedy certain remaining covenant defaults related to the FY 2014 financial restatement by incurring additional charges affected through a temporary interest rate increase and an upfront payment. Through the May 20, 2015 and November 13, 2015 debt modifications and related amortization, unamortized deferred financing fees were $10.7 million as of December 31, 2015. During the three month period ended March 31, 2016 the Company incurred an additional $1.5 million of financing costs related to the continued restatement and amortized $2.6 million of the total incremental term loan costs, as compared to $0.3 million amortized during the three month period ended March 31, 2015, resulting in $9.6 million of incremental deferred financing fees remaining at March 31, 2016. The increase in amortization of deferred financing fees in the current quarter as compared to the prior year quarter was principally the result of the deferred financing fee amortization associated with the voluntary principal repayment and increased amortization of costs due to consent modifications. The Company will amortize the remaining deferred financing fees using the effective interest method over the term of the Existing Term Loan Agreement. Subsequent to November 13, 2015, interest accrues based, at the Company’s election, on an adjusted prime/federal funds rate (“ABR Loan”) or an adjusted LIBOR (“Eurodollar Loan”) rate, plus a margin of 4.00% for ABR Loans and 5.00% for Eurodollar Loans. As of the date of the filing of this Form 10-Q until the maturity of the incremental term loan, our spread will be based upon the Ratings Level applicable on such date as documented below. Ratings Level Index Ratings (Moody’s/S&P) Eurodollar Spread ABR Spread Level I B1/B+ or higher 4.25% 3.25% Level II B2/B 4.75% 3.75% Level III B3/B- or lower 5.50% 4.50% For the three month periods ended March 31, 2016 and 2015, the Company recorded interest expense of $4.6 million and $5.0 million , respectively in relation to the Incremental Term Loan Agreement. Existing Term Loan Concurrent with the closing of its acquisition of Hi-Tech (the “Hi-Tech Acquisition”) Akorn Loan Parties entered into a $600.0 million Term Facility (the “Existing Term Facility”) pursuant to a Loan Agreement dated April 17, 2014 (the “Existing Term Loan Agreement”) between the Akorn Loan Parties as borrowers, and certain other lenders with JPMorgan, acting as administrative agent. The Company may increase the loan amount up to an additional $150.0 million , or more, provided certain financial covenants and other conditions are satisfied. The proceeds received pursuant to the Existing Term Loan Agreement were used to finance the Hi-Tech Acquisition. The Existing Term Facility is secured by all of the assets of the Akorn Loan Parties, including springing control of the Company’s primary deposit account pursuant to a deposit account control agreement. The Existing Term Loan Agreement required quarterly principal repayment equal to 0.25% of the initial loan amount of $600.0 million beginning with the second full quarter following the closing date of the Existing Term Loan Agreement, with a final payment of the remaining principal balance due at maturity seven years from the date of closing of the Existing Term Loan Agreement. The Company may prepay all or a portion of the remaining outstanding principal amount under the Existing Term Loan Agreement at any time, or from time to time, subject to prior notice to the lenders and payment of applicable fees. Prepayment of principal will be required should the Company incur any indebtedness not permitted under the Existing Term Loan Agreement, or effect the sale, transfer or disposition of any property or asset, other than in the ordinary course of business. On February 16, 2016 the Company made a voluntary prepayment of its Existing Term Loan facility of $114.8 million which settled all future quarterly principal repayments as denoted above until the date of the closing of the Existing Term Loan Agreement or April 16, 2021, although future voluntary principal repayments are permitted. Effected for the principal repayment, as of March 31, 2016 outstanding debt under the term Existing Term Loan facility was $477.7 million and the Company was in full compliance with all applicable covenants which included customary limitations on indebtedness, distributions, liens, acquisitions, investments, and other activities. Prior to November 13, 2015 interest accrued based, at the Company’s election, on an adjusted prime/federal funds rate (“ABR Loan”) or an adjusted LIBOR (“Eurodollar Loan”) rate, plus a margin of 2.50% for ABR Loans, and 3.50% for Eurodollar Loans. Each such margin would decrease by 0.25% in the event Akorn’s senior debt to EBITDA ratio for any quarter falls to 2.25 :1.00 or below. During an event of default, as defined in the Existing Term Loan Agreement, any interest rate would be increased by 2.00% per annum. Per the Existing Term Loan Agreement, the interest rate on LIBOR loans could not fall below 4.50% . On May 20, 2015 the Company modified the Existing Term Loan Facility with JPMorgan and certain other lenders to remedy certain covenant defaults related to the FY 2014 financial restatement by incurring nominal charges affected through a temporary interest rate increase and an upfront payment. On November 13, 2015 the Company again modified the Existing Term Loan Facility with JPMorgan and certain other lenders to remedy certain remaining covenant defaults related to the FY 2014 financial restatement by incurring additional charges affected through a temporary interest rate increase and an upfront payment. Through the May 20, 2015 and November 13, 2015 debt modifications and related amortization, unamortized deferred financing fees were $16.1 million as of December 31, 2015. During the three month period ended March 31, 2016 the Company incurred an additional $2.1 million of financing costs related to the continued restatement and amortized $3.5 million of the total existing term loan costs, as compared to $0.5 million amortized during the three month period ended March 31, 2015, resulting in $14.6 million of existing deferred financing fees remaining at March 31, 2016. The increase in amortization of deferred financing fees in the current quarter as compared to the prior year quarter was principally the result of the deferred financing fee amortization associated with the voluntary principal repayment and increased amortization of costs due to consent modifications. The Company will amortize the remaining deferred financing fees using the effective interest method over the term of the Existing Term Loan Agreement. Subsequent to November 13, 2015, interest accrues based, at the Company’s election, on an adjusted prime/federal funds rate (“ABR Loan”) or an adjusted LIBOR (“Eurodollar Loan”) rate, plus a margin of 4.00% for ABR Loans and 5.00% for Eurodollar Loans. As of the date of the filing of this Form 10-Q until the maturity of the existing term loan, our spread will be based upon the Ratings Level applicable on such date as documented below. Ratings Level Index Ratings (Moody’s/S&P) Eurodollar Spread ABR Spread Level I B1/B+ or higher 4.25% 3.25% Level II B2/B 4.75% 3.75% Level III B3/B- or lower 5.50% 4.50% For the three month periods ended March 31, 2016 and 2015, the Company recorded interest expense of $6.2 million and $6.7 million , respectively in relation to the Existing Term Loan. JPMorgan Credit Facility On April 17, 2014, the Akorn Loan Parties entered into a Credit Agreement (the “JPM Credit Agreement”) with JPMorgan as administrative agent, and Bank of America, N.A., as syndication agent for certain other lenders (at closing, Bank of America, N.A. and Wells Fargo Bank, N. A.) for a $150.0 million revolving credit facility (the “JPM Revolving Facility”). Subject to other conditions in the JPM Credit Agreement, advances under the JPM Revolving Facility will be made in accordance with a borrowing base consisting of the sum of the following: (a) 85% of eligible accounts receivable; (b) The lesser of: a. 65% of the lower of cost or market value of eligible raw materials and work in process inventory, valued on a first in first out basis, and b. 85% of the orderly liquidation value of eligible raw materials and work in process inventory, valued on a first in first out basis; (c) The lesser of: a. 75% of the lower of cost or market value of eligible finished goods inventory, valued on a first in first out basis, and b. 85% of the orderly liquidation value of eligible finished goods inventory, valued on a first in first out basis up to 85% of the liquidation value of eligible inventory (or 75% of market value finished goods inventory); and (d) Less any reserves deemed necessary by the administrative agent, and allowed in its permitted discretion. The total amount available under the JPM Revolving Facility includes a $10.0 million letter of credit facility. Under the terms of the JPM Credit Agreement, if availability under the JPM Revolving Facility falls below 12.5% of commitments or $15.0 million for more than 30 consecutive days, the Company may be subject to cash dominion, additional reporting requirements, and additional covenants and restrictions. The Company may seek additional commitments to increase the maximum amount of the JPM Revolving Facility to $200.0 million . Unless cash dominion is exercised by the lenders in connection with the JPM Revolving Facility, the Company will be required to repay the JPM Revolving Facility upon its expiration five years from issuance, subject to permitted extension, and will pay interest on the outstanding balance monthly based, at the Company’s election, on an adjusted prime/federal funds rate (“ABR”) or an adjusted LIBOR (“Eurodollar”), plus a margin determined in accordance with the Company’s consolidated fixed charge coverage ratio (EBITDA to fixed charges) as follows: Fixed Charge Coverage Ratio Revolver ABR Spread Revolver Eurodollar Spread Category 1 > 1.50 to 1.0 0.50% 1.50% Category 2 > 1.25 to 1.00 but < 1.50 to 1.00 0.75% 1.75% Category 3 < 1.25 to 1.00 1.00% 2.00% In addition to interest on borrowings, the Company will pay an unused line fee of 0.250% per annum on the unused portion of the JPM Revolving Facility. During an event of default, as defined in the JPM Credit Agreement, any interest rate will be increased by 2.00% per annum. The JPM Revolving Facility is secured by all of the assets of the Akorn Loan Parties, including springing control of the Company’s primary deposit account pursuant to a Deposit Account Control Agreement. The financial covenants require the Akorn Loan Parties to maintain the following on a consolidated basis: (a) Minimum Liquidity, as defined in the JPM Credit Agreement, of not less than (a) $120.0 million plus (b) 25% of the JPM Revolving Facility commitments during the three month period preceding the June 1, 2016 maturity date of the Company’s senior convertible notes. (b) Ratio of EBITDA to fixed charges of no less than 1.00 to 1.00 (measured quarterly for the trailing 4 quarters). As of March 31, 2016 the Company was in full compliance with all covenants applicable to the JPM Revolving Facility. The Company may use any proceeds from borrowings under the JPM Revolving Facility for working capital needs and for the general corporate purposes of the Company and its subsidiaries. At March 31, 2016, there were no outstanding borrowings and one outstanding letter of credit in the amount of approximately $1.5 million under the JPM Revolving Facility. Availability under the facility as of March 31, 2016 was approximately $148.5 million . The JPM Credit Agreement places customary limitations on indebtedness, distributions, liens, acquisitions, investments, and other activities of the Akorn Loan Parties in a manner designed to protect the collateral while providing flexibility for growth and the historic business activities of the Company and its subsidiaries. Convertible Notes On June 1, 2011, the Company issued $120.0 million aggregate principal amount of 3.50% Convertible Senior Notes due 2016 (the “Notes”) which included $20.0 million in aggregate principal amount of the Notes issued in connection with the full exercise by the initial purchasers of their over-allotment option. The Notes are governed by the Company’s indenture with Wells Fargo Bank, National Association, as trustee (the “Indenture”). The Notes were offered and sold only to qualified institutional buyers. The net proceeds from the sale of the Notes were approximately $115.3 million , after deducting underwriting fees and other related expenses. The Notes have a maturity date of June 1, 2016 and pay interest at an annual rate of 3.50% semiannually in arrears on June 1 and December 1 of each year, with the first interest payment completed on December 1, 2011. The Notes are convertible into shares of the Company’s common stock, cash or a combination thereof at an initial conversion price of $8.76 per share, which is equivalent to an initial conversion rate of approximately 114.1553 shares per $1,000 principal amount of Notes. The conversion price is subject to adjustment for certain events described in the Indenture, including certain corporate transactions which would increase the conversion rate and decrease the conversion price for a holder that elects to convert their Notes in connection with such corporate transaction. The conversion price has not been adjusted as of the date of this Form 10-Q. The Notes may be converted at any time at the option of the holders prior to the close of business on the business day immediately preceding December 1, 2015 under the following circumstances: (1) during any calendar quarter commencing after September 30, 2011, if the closing sale price of the Company’s common stock, for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the calendar quarter immediately preceding the calendar quarter in which the conversion occurs, is more than 130% of the conversion price in effect on each applicable trading day; (2) during the five consecutive trading-day period following any five consecutive trading-day period in which the trading price for the Notes per $1,000 principal amount of Notes for each such trading day was less than 98% of the closing sale price of the Company’s common stock on such date multiplied by the then-current conversion rate; or (3) upon the occurrence of specified corporate events. On or after December 1, 2015 until the close of business on the business day immediately preceding the stated maturity date, holders may surrender all or any portion of their Notes for conversion at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, at the Company’s option, cash, shares of the Company’s common stock, or a combination thereof. If a “fundamental change” (as defined in the Indenture) occurs prior to the stated maturity date, holders may require the Company to purchase for cash all or a portion of their Notes. The Notes became convertible effective April 1, 2012 as a result of the Company’s common stock closing above the required price of $11.39 per share for 20 of the last 30 consecutive trading days in the quarter ended March 31, 2012. The Notes have remained convertible for each successive quarter as a result of meeting the trading price requirement at the end of each prior quarter. During the year ended December 31, 2015 and 2014, approximately $44.3 million and $32.5 million of this convertible debt was converted at the holder’s request which resulted in an additional $1.2 million and $1.0 million of expense recognized due to the conversions, respectively. No debt was converted at the holder's request, in the three month period ended March 31, 2016. The Notes are not listed on any securities exchange or on any automated dealer quotation system, but are traded on a secondary market made by the initial purchasers. The initial purchasers of the Notes advised the Company of their intent to make a market in the Notes following the offering, though they are not obligated to do so and may discontinue any market making at any time. As of March 31, 2016, the face value of the notes was $43.2 million , but due to recent inactivity in the trading of the convertible notes as a result of recent conversions, bid and ask spreads, which would be used to calculate the trading value of the outstanding notes were not available and accordingly, we have not calculated the trading value of the convertible notes as of and for the three months ended March 31, 2016. The actual conversion value of the Notes is based on the product of the conversion rate and the market price of the Company’s common stock at conversion, as defined in the Indenture. As of March 31, 2016, the Company’s common stock closed at $23.53 per share, resulting in a pro forma conversion value for the Notes of approximately $116.1 million . Increases in the market value of the Company’s common stock increase the fair value of the Company’s obligation accordingly. There is no upper limit placed on the possible conversion value of the Notes. The Notes are being accounted for in accordance with ASC 470-20 - Debt with Conversion and Other Options . Under ASC 470-20 - Debt with Conversion and Other Options , issuers of convertible debt instruments that may be settled in cash upon conversion, including partial cash settlement, are required to separately account for the liability (debt) and equity (conversion option) components. The application of ASC 470-20 - Debt with Conversion and Other Options resulted in the recognition of $20.5 million as the value for the equity component. This amount was offset by $0.8 million of equity issuance costs, as described below, and both were affected by the conversion of a cumulative amount of $76.8 million of notes as documented above. At dates indicated, the net carrying amount of the liability component and the remaining unamortized debt discount were as follows (in thousands): March 31, 2016 December 31, 2015 Carrying amount of equity component $ 7,372 $ 7,372 Carrying amount of the liability component 42,912 42,465 Unamortized discount of the liability component 303 750 Unamortized deferred financing costs 55 136 The Company incurred debt issuance costs of $4.7 million related to its issuance of the Notes. In accordance with ASC 470-20 - Debt with Conversion and Other Options , the Company allocated this debt issuance cost ratably between the liability and equity components of the Notes, resulting in $3.9 million of debt issuance costs allocated to the liability component and $0.8 million allocated to the equity component. The portion allocated to the liability component was classified as deferred financing costs and is being amortized by the effective interest method through the earlier of the maturity date of the Notes or the date of conversion, while the portion allocated to the equity component was recorded as an offset to additional paid-in capital upon issuance of the Notes. During the three month periods ended March 31, 2016 and 2015, the Company recorded the following expenses in relation to the Notes (in thousands): Three months ended March 31, 2016 2015 Expense Description Interest expense at 3.5% coupon rate (1) $ 432 $ 759 Debt discount amortization 447 835 Amortization of deferred financing costs 81 151 Loss on Conversion — 73 $ 960 $ 1,818 (1) As a result of the restatement of the 2014 financial data and the resultant delays in filings of the 2015 financial statements the Company had been required to remit an additional 0.5% interest penalty to all holders of the convertible notes throughout the three month period ended March 31, 2016. Upon issuing the Notes, the Company established a deferred tax liability of $8.6 million related to the debt discount of $21.3 million, with an offsetting debit of $8.6 million to common stock. The deferred tax liability was established because the amortization of the debt discount generates non-cash interest expense that is not deductible for income tax purposes. Since the Company’s net deferred tax assets were fully reserved by valuation allowance at the time the Notes were issued, the Company reduced its valuation allowance by $8.6 million upon recording the deferred tax liability related to the debt discount with an offsetting credit of $8.6 million to common stock. As a result, the net impact of these entries was a debit of $8.6 million to the valuation reserve against the Company’s deferred tax assets and a credit of $8.6 million to deferred tax liability. The deferred tax liability is being amortized monthly as the Company records non-cash interest from its amortization of the debt discount on the Notes. Aggregate cumulative maturities of long-term obligations (including the incremental and existing term loans, convertible debt and the JPM revolver) as of March 31, 2016 are: (In thousands) 2016 2017 2018 2019 Thereafter Maturities $ 43,215 $ — $ — $ — $ 831,938

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE Basic net income per common share is based upon the weighted average number of common shares outstanding during the period. Diluted net income per common share is based upon the weighted average number of common shares outstanding, including the dilutive effect, if any, of potentially dilutive securities using the treasury stock method. Previously, diluted net income per share assumed the principal amount of the convertible Notes would be cash settled and any conversion spread would be settled using common shares, as the Company has the choice of settling either in cash or shares. The Company had demonstrated a past practice and intent of cash settlement for the principal and stock settlement of the conversion spread. As a result, earnings per share calculations for periods ended prior to and including September 30, 2014 only included the assumption of conversion to common shares for the convertible spread. During the quarter ended December 31, 2014, the Company changed its practice of cash settlement and settled redemptions using common shares for both the principal and conversion spread and accordingly, earnings per share amounts were calculated using the if-converted method. For the three month periods ended March 31, 2016 and 2015, respectively the earnings per share amounts were calculated using the if-converted method. The Company’s potentially dilutive shares consist of: (i) vested and unvested stock options that are in-the-money, (ii) unvested RSAs, and (iii) shares potentially issuable upon conversion of the Notes. A reconciliation of the earnings per share data from a basic to a fully diluted basis is detailed below (amounts in thousands, except per share data): Three Months Ended March 31, 2016 2015 Net income $ 41,886 $ 37,538 Convertible debt income adjustments, net of tax 604 1,107 Net income adjusted for convertible debt as used for diluted earnings per share $ 42,490 $ 38,645 Net income per share: Basic $ 0.35 $ 0.33 Diluted (1) $ 0.34 $ 0.31 Shares used in computing net income per share: Weighted average basic shares outstanding 119,516 113,352 Dilutive securities: Stock option and unvested RSAs 1,172 2,085 Shares issuable upon conversion of the notes 4,933 9,940 Total dilutive securities 6,105 12,025 Weighted average diluted shares outstanding 125,621 125,377 Shares subject to stock options omitted from the calculation of income per share as their effect would have been anti-dilutive 2,430 575 (1) Due to a change in the expectation that management may settle all future note conversions solely through shares in the year and quarter ended December 31, 2014, the diluted income from continuing operations per share calculation includes the dilutive effect of convertible debt and is offset by the exclusion of interest expense and deferred financing fees related to the convertible debt of $0.6 million and $1.1 million , after-tax for the three month periods ended March 31, 2016 and 2015, respectively.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
SEGMENT REPORTING	SEGMENT INFORMATION During the three month periods ended March 31, 2016 and 2015, respectively, the Company reported results for the following two reportable segments: - Prescription Pharmaceuticals - Consumer Health The Company’s Prescription Pharmaceutical segment principally consists of generic and branded Prescription Pharmaceuticals products which span a broad range of indications as well as a variety of dosage forms including: sterile ophthalmics, injectables and inhalants, and non-sterile oral liquids, topicals, nasal sprays. The Company’s Consumer Health segment principally consists of animal health and OTC products, both branded and private label. OTC products include a suite of products for the treatment of dry eye sold under the TheraTears ® brand name. Financial information about the Company’s reportable segments is based upon internal financial reports that aggregate certain operating information. The Company’s Chief Operating Decision Maker (“CODM”), as defined in ASC 280 - Segment Reporting , and CEO, oversees operational assessments and resource allocations based upon the results of the Company’s reportable segments, which have available and discrete financial information. Selected financial info by reportable segment is presented below (in thousands). Three Months Ended March 31, 2016 2015 Revenues: Prescription Pharmaceuticals $ 250,749 $ 210,554 Consumer Health 17,598 16,824 Total revenues 268,347 227,378 Gross Profit: Prescription Pharmaceuticals 154,635 121,159 Consumer Health 8,382 9,004 Total gross profit 163,017 130,163 Operating expenses 75,438 56,896 Operating income 87,579 73,267 Other expense (21,007 ) (14,939 ) Income before income taxes $ 66,572 $ 58,328 The Company manages its business segments to the gross profit level and manages its operating and other costs on a company-wide basis. Inter-segment activity at the gross profit level is minimal. The Company does not have discrete assets by segment, as certain manufacturing and warehouse facilities support more than one segment, and therefore does not report assets by segment.

Business Combinations, Disposit

Business Combinations, Dispositions and Other Strategic Investments	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
BUSINESS COMBINATIONS, DISPOSITIONS AND OTHER STRATEGIC INVESTMENTS	BUSINESS COMBINATIONS AND OTHER STRATEGIC INVESTMENTS Akorn AG (formerly Excelvision AG) On July 22, 2014, Akorn International S.à r.l., entered into a share purchase agreement with Fareva SA, a private company headquartered in France to acquire all of the issued and outstanding shares of capital stock of its wholly owned subsidiary, Excelvision AG for 21.7 million CHF (“Swiss Francs”), net of certain working capital amounts and inventory amounts, Excelvision AG was a contract manufacturer located in Hettlingen, Switzerland specializing in ophthalmic products. On January 2, 2015, the Company acquired all of the outstanding shares of capital stock of Excelvision AG for $28.4 million U.S. dollars (“USD”) funded through available cash on hand. The Company’s acquisition of Excelvision AG is being accounted for as a business combination in accordance with ASC 805 - Business Combinations . The purpose of the acquisition is to expand the Company’s manufacturing capacity. On April 1, 2016 the name of Excelvision AG was changed to Akorn AG. During the three month periods ended March 31, 2016 and 2015, the Company recorded $0 and approximately $0.1 million , respectively in acquisition-related expenses in connection with the Akorn AG Acquisition. These expenses principally consisted of various legal fees and other acquisition costs which have been recorded within “acquisition related costs” as part of operating expenses in the Company’s condensed consolidated statement of comprehensive income. The following table sets forth the consideration paid for the Akorn AG Acquisition and the fair values of the acquired assets and assumed liabilities (in millions of USD) as of the acquisition date adjusted in accordance with GAAP. The figures below may differ from historical financial results of Akorn AG. Consideration: Amount of cash paid $ 25.9 Outstanding amount payable to Fareva 2.5 Total consideration at closing $ 28.4 Recognized amounts of identifiable assets acquired: Cash and cash equivalents $ 1.2 Accounts receivable 3.4 Inventory 4.2 Other current assets 0.9 Property and equipment 26.6 Total assets acquired 36.3 Assumed current liabilities (1.7 ) Assumed non-current liabilities (3.9 ) Deferred tax liabilities (1.4 ) Total liabilities assumed (7.0 ) Bargain purchase gain (0.9 ) Fair value of assets acquired $ 28.4 Through its acquisition of Akorn AG the Company recognized a bargain purchase gain of $0.9 million which was largely derived from the difference between the fair value and the book value of the property and equipment acquired through the acquisition. Bargain purchase gain has been recognized within net income for the three month period ended March 31, 2015. During the three month periods ended March 31, 2016 and 2015, the Company recorded net revenue of approximately $6.9 million and $6.5 million , respectively related to sales from the Akorn AG location subsequent to acquisition. Other Strategic Investments On August 1, 2011, the Company entered into a Series A-2 Preferred Stock Purchase Agreement to acquire a minority ownership interest in Aciex Therapeutics Inc. (“Aciex”), a private ophthalmic development pharmaceutical company based in Westborough, MA, for $8.0 million in cash. Subsequently, on September 30, 2011, the Company entered into Amendment No. 1 to Series A-2 Preferred Stock Purchase Agreement to acquire additional shares of Series A-2 Preferred Stock in Aciex for approximately $2.0 million in cash. On April 17, 2014, the Company entered into a Secured Note and Warrant Purchase Agreement to acquire secured, convertible promissory notes of Aciex for approximately $0.4 million in cash. On June 27, 2014, the Company entered into a second Secured Note and Warrant Purchase Agreement to acquire additional secured, convertible promissory notes of Aciex for an additional amount of approximately $0.4 million . The Company’s aggregate investment in Aciex is $10.8 million at cost. Aciex was an ophthalmic drug development company focused on developing novel therapeutics to treat ocular diseases. Aciex’s pipeline consists of both clinical stage assets and pre-Investigational new drug stage assets. The investments detailed above provided the Company with an ownership interest in Aciex of below 20% . The Aciex Agreement and Aciex Amendment contain certain customary rights and preferences over the common stock of Aciex and further provide that the Company shall have the right to a seat on the Aciex board of directors. On July 2, 2014 Nicox S.A., (“Nicox”) an international company entered into an arrangement to acquire all of the outstanding equity of Aciex (the “Aciex Acquisition”). On October 22, 2014 Nicox shareholders voted at the Nicox General Meeting, to approve the Aciex Acquisition. The transaction was consummated on October 24, 2014, following the completion of certain legal conditions and formalities. As consideration for its carried investment in Aciex, the Company received from the Aciex Acquisition pro-rata shares of Nicox which are publically traded on the Euronext Paris exchange. Through the closing the Company received approximately 4.3 million shares of Nicox which were subject to certain lockup provisions preventing immediate sale of underlying shares received for the Company’s investment in an available for sale security. Through the years ended December 31, 2015 and 2014 the Company sold 1.1 million and 0.2 million unrestricted shares for approximately $2.6 million and $0.6 million realizing a loss of $0.2 million and an immaterial gain on the sale of shares, respectively. There were no share sales for the three months ended March 31, 2016. In accordance with ASC 820 Fair Value Measurement , the Company records unrealized holding gains and losses on available for sale securities in the “Accumulated other comprehensive income” caption in the condensed consolidated Balance Sheet. For the three months ended March 31, 2016 the Company recognized an unrealized holding loss, net of tax of $2.7 million as calculated based on the discounted value of the investment given the contractual lockup provisions. The Company has determined that of the $4.9 million of unrealized fair value associated with the investment, all $4.9 million is available to be converted to cash within one year from the balance sheet date and has been classified as a current asset.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES The Company has entered into strategic business agreements for the development and marketing of finished dosage form pharmaceutical products with various pharmaceutical development companies. Each strategic business agreement includes a future payment schedule for contingent milestone payments and in certain strategic business agreements, minimum royalty payments. The Company will be responsible for contingent milestone payments and minimum royalty payments to these strategic business partners based upon the occurrence of future events. Each strategic business agreement defines the triggering event of its future payment schedule, such as meeting product development progress timelines, successful product testing and validation, successful clinical studies, various FDA and other regulatory approvals and other factors as negotiated. None of the contingent milestone payments or minimum royalty payments are individually material to the Company. The Company is engaged in various supply agreements with third parties which obligate the Company to purchase various API or finished products at contractual minimum levels. None of these agreements are individually or in aggregate material to the Company. Further, the Company does not believe at this time that any of the purchase obligations represent levels above that of normal business demands. The table below summarizes contingent potential milestone payments due to strategic partners in the years 2016 and beyond, assuming all such contingencies occur (in thousands): Year ending December 31, Amount 2016 $ 13,153 2017 4,418 2018 1,771 2019 and Beyond — Total $ 19,342 Legal Proceedings The Company is a party to legal proceedings and potential claims arising in the ordinary course of our business. The amount, if any, of ultimate liability with respect to such matters cannot be determined. Despite the inherent uncertainties of litigation, management of the Company believes that the ultimate disposition of such proceedings and exposure will not have a material adverse impact on the financial condition, results of operations, or cash flows of the Company. Set forth below is a listing of potentially material legal proceedings of the Company in existence as of the date of filing this Quarterly Report on Form 10-Q. Shareholder and Derivative Litigation. On March 4, 2015, a purported class action complaint was filed entitled Yeung v. Akorn, Inc., at el. , in the federal district court of Northern District of Illinois, No. 15-cv-1944. The complaint alleged that the Company and three of its officers violated the federal securities laws in connection with matters related to its accounting and financial reporting in the wake of its acquisitions of Hi-Tech Pharmaceutical Co., Inc. and VersaPharm, Inc. A second, related case entitled Sarzynski v. Akorn, Inc., et al. , No. 15- cv-3921, was filed on May 4, 2015 making similar allegations. On August 24, 2015, the two cases were consolidated and a lead plaintiff appointed in In re Akorn, Inc. Securities Litigation. No motions or answer have been filed in the case. The Company's board of directors also received shareholder demand letters and two shareholder derivative lawsuits have been filed alleging breaches of fiduciary duty in connection with the Company' s accounting for its acquisition and restatement of its financials. The cases, Safriet v. Rai, et al. , No. 15-cv-7275, and Glaubach v. Rai, et al. , No. 15- 11129, both filed in the Northern District of Illinois have been stayed pending anticipated rulings on any motions to dismiss the defendants may file in In re Akorn, Inc. Securities Litigation. On March 8, 2016, an additional case was filed, Kogut v. Akorn, Inc., et al. , in Louisiana state court in the Parish of East Baton Rouge, No. 646474. The Kogut action seeks an order requiring the Company to make its pending SEC filings, issue audited financial statements for the years ended December 31, 2014 and 2015, and hold its annual shareholder meeting. Fera Pharmaceuticals, LLC v. Akorn Inc., Sean Brynjelsen, and Michael Stehn , in the United States District Court for the Southern District of New York, Case No. 12-cv-07692-LLS. Fera Pharmaceuticals, LLC ("Fera") filed this action on September 12, 2012. The defendants in the case are the Company and two of its employees, Sean Brynjelsen and Michael Stehn. The amended complaint generally alleges that the Company breached certain terms of a contract manufacturing supply agreement by, among other things, failing to manufacture Fera's products, raising the manufacturing cost, and impermissibly terminating the contract. In addition, Fera alleges that the Company misappropriated Fera's trade secrets in order to manufacture Erythromycin and Bacitracin for its own benefit. The counts in the amended complaint are for (1) breach of contract, (2) misappropriation of trade secrets, (3) fraudulent inducement, and (4) declaratory and injunctive relief. Fera seeks $135 million in compensatory damages, an additional, unspecified amount in punitive damages, and injunctive relief restraining the Company from selling the products at issue in the case. The Company filed a counterclaim against Fera and certain affiliates, as well as Perrigo Company of Tennessee and Perrigo Company plc, asserting violations of Sections 1 and 2 of the Sherman Act and tortious interference with business relations. The case is still in the discovery phase, and no trial date has been scheduled. State of Louisiana v. Abbott Laboratories, Inc., et al. , The Louisiana Attorney General filed suit, Number 624,522, Nineteenth Judicial District Court, Parish of East Baton Rouge, including Hi-Tech Pharmacal, and other defendants in Louisiana state court. Louisiana's complaint alleges that the defendants violated Louisiana state laws in connection with Medicaid reimbursement for certain vitamins, dietary supplements, and DESI products that were allegedly ineligible for reimbursement. The defendants filed exceptions of no cause of action and no right of action in response to Louisiana’s amended complaint. In a judgment entered on October 2, 2015, the trial court sustained the defendants' exception of no right of action, which dismissed all of Louisiana's claims. Louisiana sought appellate review of the court's decision by filing an application for supervisory writs, as well as an appeal pending in the First Circuit Court of Appeal in Louisiana. In addition to the foregoing matters, Akorn has received shareholder demands for legal action to be taken against certain of the Company's directors and officers based on alleged breaches of fiduciary duties and other misconduct in connection with the Company's pending restatement of financial results and other matters. Akorn's Board of Directors formed a special committee to conduct an inquiry into the demand allegations and to provide its conclusions and recommendations to the Board. Former Hi-Tech director and employee Reuben Seltzer delivered to the Company a demand letter in August 2014 alleging that the Company breached his employment agreement and improperly terminated Mr. Seltzer’s employment. Mr. Seltzer further alleges that he is entitled to compensation in the approximate amount of $5.2 million . The Company disputes these claims and intends to vigorously defend these allegations. Other Matters The Chicago Regional Office of the SEC is conducting an investigation regarding the previously disclosed restatement, internal controls and other related matters. Additionally, the United States Attorney's Office for the Southern District of New York ("USAO") has requested information regarding these matters. Akorn has been furnishing requested information and is fully cooperating with the SEC and USAO. The legal matters discussed above could result in losses, including damages, fines and civil penalties, and criminal charges, which could be substantial. We record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. As of the date of this filing, although the Company has determined that liabilities associated with these legal matters are reasonably possible, they cannot be reasonably estimated. Given the nature of the litigation and investigations discussed above and the complexities involved, the Company is unable to reasonably estimate a possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation or investigation. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.

Customer and Supplier Concentra

Customer and Supplier Concentration	3 Months Ended
	Mar. 31, 2016
Risks and Uncertainties [Abstract]
Customer and Supplier Concentration	CUSTOMER AND SUPPLIER CONCENTRATION Customer Concentrations A significant percentage of the Company’s sales are to three large wholesale drug distributors: AmerisourceBergen Corporation; Cardinal Health, Inc. and McKesson Corporation. These three wholesalers (the “Big 3 Wholesalers”) are all distributors of the Company’s products, as well as suppliers of a broad range of health care products. The following table sets forth the percentage of the Company’s gross and net sales for the three month periods ended March 31, 2016 and 2015, and gross accounts receivable as of March 31, 2016 and December 31, 2015, attributable to the Big 3 Wholesalers: Three months ended March 31, Big 3 Wholesalers combined : 2016 2015 Percentage of gross sales 79% 76% Percentage of net sales revenues 67% 67% March 31, 2016 December 31, 2015 Percentage of gross trade accounts receivable 79% 83% If sales to any of the Big 3 Wholesalers were to diminish or cease, the Company believes that the end users of its products would have little difficulty obtaining the Company’s products either directly from the Company or from another distributor. No other customers accounted for more than 10% of gross sales, net revenues or gross trade receivables for the indicated dates and periods. Supplier Concentrations The Company requires a supply of quality raw materials and components to manufacture and package pharmaceutical products for its own use and for third parties with which it has contracted. The principal components of the Company’s products are active and inactive pharmaceutical ingredients and certain packaging materials. Certain of these ingredients and components are available from only a single source and, in the case of certain of the Company’s abbreviated new drug applications and new drug applications, only one supplier of raw materials has been identified. Because FDA approval of drugs requires manufacturers to specify their proposed suppliers of active ingredients and certain packaging materials in their applications, FDA approval of any new supplier would be required if active ingredients or such packaging materials were no longer available from the specified supplier. The qualification of a new supplier could delay the Company’s development and marketing efforts. In addition, certain of the pharmaceutical products marketed by the Company are manufactured by a partnered third party manufacturer, which serves as the Company’s sole source of that finished product. If for any reason the Company is unable to obtain sufficient quantities of any of the raw materials or components required to produce and package its products, it may not be able to manufacture its products as planned, which could have a material adverse effect on the Company’s business, financial condition and results of operations. Likewise, if the Company’s manufacturing partners experience any similar difficulties in obtaining raw materials or in manufacturing the finished product, the Company’s results of operations would be negatively impacted. No individual supplier represented 10% or more of the Company’s purchases in either of the three month periods ended March 31, 2016 or 2015. Product Concentrations In the three month period ended March 31, 2016 one unapproved Prescription Pharmaceutical product represented approximately 18% of the Company’s total net sales revenue. Comparatively in the three month period ended March 31, 2015 one Prescription Pharmaceutical product represented approximately 10% of the Company's total net sales revenue. The Company attempts to minimize the risk associated with product concentrations by continuing to acquire and develop new products to add to its existing portfolio.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The following table sets forth information about the Company’s income tax provision for the periods indicated (dollar amounts in thousands): Three Months ended March 31, 2016 2015 Income before income taxes $ 66,572 $ 58,328 Income tax provision 24,686 20,790 Net income $ 41,886 $ 37,538 Income tax provision/benefit as a percentage of income before income taxes 37.1 % 35.6 % During the three month period ended March 31, 2016, the Company recorded an income tax provision of $24.7 million , which equals 37.1% of income before income tax. The Company anticipates that its effective tax rate for the year 2016 will be approximately 37.0% . During the three month period ended March 31, 2015, the Company recorded a income tax provision that equaled 35.6% of income before income tax in the applicable period. The income tax provision rates in the current year was increased in comparison to the prior year due to losses at the Company’s Indian and Swiss subsidiaries. As of March 31, 2016, the Company could not conclude that it was more likely than not that tax benefits from certain of these net operating losses would be realized. Accordingly, the Company established for certain of the losses at its Indian subsidiary and the entire amount of the loss at its Swiss subsidiary. In accordance with ASC 740-10-25, Income Taxes - Recognition , the Company reviews its tax positions to determine whether it is “more likely than not” that its tax positions will be sustained upon examination, and if any tax positions are deemed to fall short of that standard, the Company establishes reserves based on the financial exposure and the likelihood that its tax positions would not be sustained. Based on its evaluations, the Company determined that it would not recognize tax benefits on $2.4 million and $2.3 million related to uncertain tax positions as of March 31, 2016 and December 31, 2015, respectively. If recognized, $1.6 million of these tax positions will impact the Company’s effective rate with the remaining $0.8 million affecting goodwill.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	RELATED PARTY TRANSACTIONS During the three month periods ended March 31, 2016 and 2015, the Company obtained legal services totaling $0.3 million and $0.2 million respectively, of which $0.1 million and $0.1 million was payable as of March 31, 2016 and 2015, respectively to Polsinelli PC (formerly Polsinelli Shughart PC), a law firm for which the spouse of the Company’s Senior Vice President, General Counsel and Secretary is an attorney and shareholder.

New Accounting Pronouncements

New Accounting Pronouncements	3 Months Ended
	Mar. 31, 2016
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	NEW ACCOUNTING PRONOUNCEMENTS Recently issued accounting pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-08 - Revenue from Contracts with Customers: Principal versus Agent Considerations . The amendments of this standard are intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. The effective date for ASU 2016-08 is the same as the effective date for ASU 2014-09 and ASU 2015-14 . The Company is currently evaluating the impact that ASU 2016-08 will have on its statement of financial position or financial statement disclosures. In February 2016, the FASB issued ASU 2016-02 - Leases which establishes a comprehensive new lease accounting model. The new standard clarifies the definition of a lease and causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding right-of-use asset for leases with a lease term of more than one year. ASU 2016-02 is effective for financial statements issued for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The new standard requires a modified retrospective transition for capital or operating leases existing at or entered into after the beginning of the earliest comparative period presented in the financial statements, but it does not require transition accounting for leases that expire prior to the date of initial application. The Company is currently evaluating the impact that ASU 2016-02 will have on its statement of financial position or financial statement disclosures. In August 2015, the FASB issued ASU No. 2015-14 - Revenue from Contracts with Customers (Topic 606) - Deferral of the Effective Date , which defers the effective date of ASU 2014-09 for one year and permits early adoption as early as the original effective date of ASU 2014-09 . The new revenue standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The Company is currently evaluating the impact that ASU 2014-09 will have on its statement of financial position or financial statement disclosures. In July 2015, the FASB issued ASU 2015-12 - Plan Accounting: Defined Benefit Plans (Topic 960) Defined Contribution Pension Plans (Topic 962) Health and Welfare Benefit Plans (Topic 965). The standard (1) requires an employee benefit plan to use contract value as the only measurement amount for fully benefit-responsive investment contracts, (2) simplifies and increases the effectiveness of plan investment disclosure requirements for employee benefit plans, and (3) provides employee benefit plans with a measurement-date practical expedient. The standard will be effective for the Plan beginning in fiscal year 2017, with early adoption permitted. The Company is currently evaluating the ASU 2015-12 will have on its statement of financial position or financial statement disclosures. In July 2015, the FASB issued ASU 2015-11 - Inventory . ASU 2015-11 simplifies the measurement of inventory by requiring inventory to be measured at the lower of cost and net realizable value. ASU 2015-11 is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company is currently evaluating the impact that ASU 2015-11 will have on its statement of financial position or financial statement disclosures. In August 2014, the FASB issued ASU 2014-15 - Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company is currently evaluating the impact that ASU 2014-15 will have on its statement of financial position or financial statement disclosures. In May 2014, FASB issued ASU 2014-09 - Revenue from Contracts with Customers , which provides guidance for revenue recognition. ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets and supersedes the revenue recognition requirements in ASC 605 - Revenue Recognition, and most industry-specific guidance. This ASU also supersedes some cost guidance included in ASC 605-35 - Revenue Recognition-Construction-Type and Production-Type Contracts . The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled in exchange for those goods or services. In doing so, companies will be required to use more judgment and make more estimates than under previous guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company for the fiscal year beginning January 1, 2017 and, at that time the Company may adopt the new standard under the full retrospective approach or the modified retrospective approach, as permitted under the standard. Early adoption of the standard is not permitted. The Company is currently evaluating the impact that ASU 2014-09 will have on its statement of financial position or financial statement disclosures. Recently adopted accounting pronouncements In March 2016, the FASB issued ASU 2016-09 - Compensation - Stock Compensation , which simplifies the accounting for the tax effects related to stock based compensation, including adjustments to how excess tax benefits and a company's payments for tax withholdings should be classified, amongst other items. ASU 2016-09 is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. ASU 2016-09 was early adopted by the Company for the year beginning January 1, 2016 and did not have a material impact on the Company's condensed consolidated financial statements or financial statement disclosures. In November 2015, the FASB issued ASU 2015-17 - Balance Sheet Classification of Deferred Taxes to simplify the presentation of deferred income taxes. ASU 2015-17 - Balance Sheet Classification of Deferred Taxes requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. ASU 2015-17 - Balance Sheet Classification of Deferred Taxes is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. ASU 2015-17 - Balance Sheet Classification of Deferred Taxes was early adopted by the Company for the year beginning January 1, 2016 resulting in the reclassification of the current portion of deferred tax assets to non-current deferred tax assets for both the quarter ended March 31, 2016 and the year ended December 31, 2015. In September 2015, the FASB issued ASU 2015-16 - Business Combinations . ASU 2015-16 - Business Combinations simplifies the accounting for measurement-period adjustments by requiring adjustments to provisional amounts in a business combination to be recognized in the reporting period in which the adjustment amounts are determined and eliminates the requirement to retrospectively account for those adjustments. ASU 2015-16 - Business Combinations requires an entity to present separately on the face of the income statement or disclose in the notes the amount recorded in current-period earnings that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 - Business Combinations was adopted by the Company for the year beginning January 1, 2016 and did not have a material impact on the Company's condensed consolidated financial statements or financial statement disclosures. In April 2015, the FASB issued ASU 2015-03 , which simplifies the presentation of debt issuance costs by requiring that debt issuance costs be presented in the balance sheet as a direct deduction from the carrying amount of debt liability, consistent with debt discounts or premiums. ASU 2015-03 is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. ASU 2015-03 was adopted by the Company for the year beginning January 1, 2016 resulting in the reclassification of the deferred financing fees to the respective face value of debt outstanding for both the quarter ended March 31, 2016 and the year ended December 31, 2015.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Consolidation	Consolidation: The accompanying condensed consolidated financial statements include the accounts of Akorn, Inc. and its wholly owned domestic and foreign subsidiaries. All inter-company transactions and balances have been eliminated in consolidation, and the financial statements of Akorn India Private Limited ("AIPL") and Akorn AG (formerly "Excelvision AG" or "Hettlingen") have been translated from Indian Rupees to U.S. Dollars and Swiss Francs to U.S. dollars, respectively based on the currency translation rates in effect during the period or as of the date of consolidation, as applicable. The Company has no involvement with variable interest entities.
Use of Estimates	Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. Significant estimates and assumptions for the Company relate to the allowances for chargebacks, rebates, product returns, coupons, promotions and doubtful accounts, as well as the reserve for slow-moving and obsolete inventories, the carrying value and lives of intangible assets, the useful lives of fixed assets, the carrying value of deferred income tax assets and liabilities, the assumptions underlying share-based compensation, accrued but unreported employee benefit costs and assumptions underlying the accounting for business combinations.
Revenue Recognition	Revenue Recognition: Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the sales price is fixed or determinable, and collectability is reasonably assured. Revenue from product sales are recognized when title and risk of loss have passed to the customer. Provision for estimated chargebacks, rebates, discounts, managed care rebates, product returns and doubtful accounts is made at the time of sale and is analyzed and adjusted, if necessary, at each balance sheet date. Freight: The Company records amounts billed to customers for shipping and handling as revenue, and records shipping and handling expense related to product sales as cost of sales.
Cash and Cash Equivalents	Cash and Cash Equivalents: The Company considers all unrestricted, highly liquid investments with maturity of three months or less when acquired, to be cash and cash equivalents.
Accounts Receivable	Accounts Receivable: Trade accounts receivables are stated at their net realizable value. The nature of the Company’s business involves, in the ordinary course, significant judgments and estimates relating to chargebacks, coupon redemption, product returns, rebates, discounts given to customers and allowances for doubtful accounts. Depending on the products, the customers, the specific terms of national supply contracts and the particular arrangements with the Company’s wholesaler customers, certain rebates, chargebacks and other credits are recorded as deductions to the Company’s trade accounts receivable. Unless otherwise noted, the provisions and allowances for the following customer deductions are reflected in the accompanying condensed consolidated financial statements as reductions of revenues and trade accounts receivable, respectively.
Chargebacks and Rebates	Chargebacks, Rebates, Discounts and Other Adjustments: The Company enters into contractual agreements with certain third parties such as retailers, hospitals, group-purchasing organizations ("GPOs") and managed care organizations to sell certain products at predetermined prices. Similarly, we maintain an allowance for rebates and discounts related to billbacks, wholesaler service fee for service contracts, GPO administrative fees, government programs, prompt payment and other adjustments with certain customers. Most of the parties have elected to have these contracts administered through wholesalers that buy the product from the Company and subsequently sell it to these third parties. When a wholesaler sells products to one of these third parties that are subject to a contractual price agreement, the difference between the price paid to the Company by the wholesaler and the price under the specific contract is charged back to the Company by the wholesaler. The Company tracks sales and submitted chargebacks by product number and contract for each wholesaler. Utilizing this information, the Company estimates a chargeback percentage for each product and records an allowance as a reduction to gross sales when the Company records its sale of the products. The Company reduces the chargeback allowance when a chargeback request from a wholesaler is processed. Actual chargebacks processed by the Company can vary materially from period to period based upon actual sales volume through the wholesalers. However, the Company’s provision for chargebacks is fully reserved for at the time when sales revenues are recognized. Management obtains certain wholesaler inventory reports to aid in analyzing the reasonableness of the chargeback allowance and which are additionally monitored to ensure that wholesaler inventory levels by product do not significantly exceed underlying customer demand. The Company assesses the reasonableness of its chargeback allowance by applying the product chargeback percentage based on a combination of historical activity and future price and mix expectations to the quantities of inventory on hand at the wholesaler per wholesaler inventory reports. In accordance with its accounting policy, the Company estimates the percentage amount of wholesaler inventory that will ultimately be sold to third parties that are subject to contractual price agreements based on a trend of such sales through wholesalers. The Company uses this percentage estimate until historical trends indicate that a revision should be made. On an ongoing basis, the Company evaluates its actual chargeback rate experience, and new trends are factored into its estimates each quarter as market conditions change. Similarly, the Company maintains an allowance for rebates related to contract and other programs with certain customers. Rebate percentages vary by product and by volume purchased by each eligible customer. The Company tracks sales by product number for each eligible customer and then applies the applicable rebate percentage, using both historical trends and actual experience to estimate its rebate allowance. The Company reduces gross sales and increases the rebate allowance by the estimated rebate amount when the Company sells its products to its rebate-eligible customers. The Company reduces the rebate allowance when it processes a customer request for a rebate. At each balance sheet date, the Company analyzes the allowance for rebates against actual rebates processed and makes necessary adjustments as appropriate. Actual rebates processed can vary materially from period to period. Other adjustments consist primarily of price adjustments, also known as “shelf-stock adjustments” and “price protections,” which are both credits issued to reflect increases or decreases in the invoice or contract prices of the Company’s products. In the case of a price decrease a credit is given for product remaining in customer’s inventories at the time of the price reduction. Contractual price protection results in a similar credit when the invoice or contract prices of the Company’s products increase, effectively allowing customers to purchase products at previous prices for a specified period of time. Amounts recorded for estimated shelf-stock adjustments and price protections are based upon specified terms with direct customers, estimated changes in market prices, and estimates of inventory held by customers. The Company regularly monitors these and other factors and evaluates the reserve as additional information becomes available. Other adjustments also include prompt payment discounts.
Sales Returns	Sales Returns: Certain of the Company’s products are sold with the customer having the right to return the product within specified periods and guidelines for a variety of reasons, including but not limited to, pending expiration dates. Provisions are made at the time of sale based upon tracked historical experience. Historical factors such as one-time events as well as pending new developments that would impact the expected level of returns are taken into account to determine the appropriate reserve estimate at each balance sheet date. As part of the evaluation of the balance required, the Company considers actual returns to date that are in process, the expected impact of any product recalls and the wholesaler’s inventory information to assess the magnitude of unconsumed product that may result in sales returns to the Company in the future. The sales returns level can be impacted by factors such as overall market demand and market competition and availability for substitute products which can increase or decrease the pull through for sales of the Company’s products and ultimately impact the level of sales returns. Actual returns experience and trends are factored into the Company’s estimates each quarter as market conditions change. Actual returns processed can vary materially from period to period.
Allowance for Coupons, Promotions and Co-Pay discount cards	Allowance for Coupons, Promotions and Co-Pay discount cards: The Company issues coupons from time to time that are redeemable against certain of our Consumer Health products. Upon release of coupons into the market, the Company records an estimate of the dollar value of coupons expected to be redeemed. This estimate is based on historical experience and is adjusted as needed based on actual redemptions. In addition to couponing, from time to time the Company authorizes various retailers to run in-store promotional sales of its products. Upon receiving confirmation that a promotion was run, the Company accrues an estimate of the dollar amount expected to be owed back to the retailer. This estimate is trued up to actual upon receipt of the invoice from the retailer. Additionally, the Company provides consumer co-pay discount cards, administered through outside agents to provide discounted products when redeemed. Upon release of the cards into the market, the Company records an estimate of the dollar value of co-pay discounts expected to be utilized. This estimate is based on historical experience and is adjusted as needed based on actual usage.
Doubtful Accounts	Doubtful Accounts: Provisions for doubtful accounts, which reflect trade receivable balances owed to the Company that are believed to be uncollectible, are recorded as a component of selling, general and administrative ("SG&A") expenses. In estimating the allowance for doubtful accounts, the Company considers its historical experience with collections and write-offs, the credit quality of its customers and any recent or anticipated changes thereto, and the outstanding balances and past due amounts from its customers. Note that in the ordinary course of business, and consistent with our peers, we may from time to time offer extended payment terms to our customers as an incentive for new product launches and in other circumstances in accordance with industry practices. These extended payment terms do not represent a significant risk to the collectability of accounts receivable as of the period-end and are evaluated in accordance with Accounting Standards Codification (ASC) 605 - Revenue Recognition as applicable. Accounts are considered past due when they remain uncollected beyond the due date specified in the applicable contract or on the applicable invoice, whichever is deemed to take precedence.
Advertising and Promotional Allowances to Customers	Advertising and Promotional Allowances to Customers: The Company routinely sells its consumer health products to major retail drug chains. From time to time, the Company may arrange for these retailers to run in-store promotional sales of the Company’s products. The Company reserves an estimate of the dollar amount owed back to the retailer, recording this amount as a reduction to revenue at the later of the date on which the revenue is recognized or the date the sales incentive is offered. When the actual invoice for the sales promotion is received from the retailer, the Company adjusts its estimate accordingly. Advertising and promotional expenses paid to customers are expensed as incurred in accordance with ASC 605-50 - Customer Payments and Incentives .
Inventories	Inventories: Inventories are stated at the lower of cost (average cost method) or market. The Company maintains an allowance for slow-moving and obsolete inventory as well as inventory where the cost is in excess of its net realizable value. For finished goods inventory, the Company estimates the amount of inventory that may not be sold prior to its expiration or is slow moving based upon review of recent sales activity and wholesaler inventory information. The Company also analyzes its raw material and component inventory for slow moving items. The Company capitalizes inventory costs associated with its products prior to regulatory approval when, based on management judgment, future commercialization is considered probable and future economic benefit is expected to be realized. The Company assesses the regulatory approval process and where the product stands in relation to that approval process including any known constraints or impediments to approval. The Company also considers the shelf life of the product in relation to the product timeline for approval.
Intangible Assets	Intangible Assets: Intangible assets consist primarily of goodwill and in-process research and development, which are carried at initial value and subject to evaluation for impairment, and product licensing costs, trademarks and other such costs, which are capitalized and amortized on a straight-line basis over their useful lives, normally ranging from one year to thirty years . The Company regularly assesses its intangible assets for impairment based on several factors, including estimated fair value and anticipated cash flows. If the Company incurs additional costs to renew or extend the life of an intangible asset, such costs are added to the remaining unamortized cost of the asset, if any, and the sum is amortized over the extended remaining life of the asset. Goodwill is tested for impairment annually or more frequently if changes in circumstances or the occurrence of events suggest that impairment may exist. The Company uses widely accepted valuation techniques to determine the fair value of its reporting units used in its annual goodwill impairment analysis. The Company’s valuation is primarily based on qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. The Company models the fair value of the reporting unit based on projected earnings and cash flows of the reporting unit.
Property, Plant and Equipment	Property, Plant and Equipment: Property, plant and equipment is stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method in amounts considered sufficient to amortize the cost of the assets to operations over their estimated useful lives or capital lease terms. The amortization of assets under capital leases is included within depreciation expense.
Net Income Per Common Share	Net Income Per Common Share: Basic net income per common share is based upon weighted average common shares outstanding. Diluted net income per common share is based upon the weighted average number of common shares outstanding, including the dilutive effect, if any, of stock options and convertible securities using the treasury stock and if converted methods. Anti-dilutive shares are excluded from the computation of diluted net income per share.
Income Taxes	Income Taxes: Income taxes are accounted for under the asset and liability method. Deferred income tax assets and liabilities are recognized for the tax effects of temporary differences between the financial reporting and tax bases of assets and liabilities, and net operating loss and other tax credit carry-forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce the recognized deferred tax assets to the amount that is more likely than not to be realized.
Fair Value of Financial Instruments	Fair Value of Financial Instruments: The Company applies ASC 820 - Fair Value Measurement , which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 - Fair Value Measurement defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 - Fair Value Measurement generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability, and are to be developed based on the best information available in the circumstances. The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below: - Level 1 —Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. The carrying value of the Company‘s cash and cash equivalents and the portion of the value of the Nicox S.A. ("Nicox") shares which are available to be traded on the exchange are considered Level 1 assets. - Level 2 —Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. - Level 3 —Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. The portion of the fair valuation of the available for sale investment held in shares of Nicox S.A. ("Nicox") subject to a lock-up provision is considered a Level 3 asset. The additional consideration payable as a result of the ECR divestiture and other insignificant contingent amounts are considered Level 3 liabilities.
Stock-Based Compensation	Stock-Based Compensation: Stock-based compensation cost is estimated at grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. The Company uses the Black-Scholes model for estimating the grant date fair value of stock options. Determining the assumptions to be used in the model is highly subjective and requires judgment. The Company uses an expected volatility that is based on the historical volatility of its common stock. The expected life assumption is based on historical employee exercise patterns and employee post-vesting termination behavior. The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities of similar term in effect during the quarter in which the options were granted. The dividend yield reflects the Company’s historical experience as well as future expectations over the expected term of the option. The Company estimates forfeitures at the time of grant and revises the estimate in subsequent periods, as necessary, if actual forfeitures differ from initial estimates.
Business Combinations	Business Combinations: Business combinations are accounted for in accordance with ASC 805 - Business Combinations , using the acquisition method of accounting. The acquisition method of accounting requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill reflects the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received. Under the acquisition method of accounting, the Company will identify the acquirer and the closing date and apply applicable recognition principles and conditions. Acquisition-related costs are costs the Company incurs to effect a business combination. The Company accounts for acquisition-related costs as expenses in the periods in which the costs are incurred.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis used to measure the fair value of financial instruments	The following table summarizes the basis used to measure the fair values of the Company’s financial instruments (amounts in thousands): Fair Value Measurements at Reporting Date, Using: Description March 31, 2016 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash and cash equivalents $ 140,998 $ 140,998 $ — $ — Available-for-sale securities 4,901 4,010 — 891 Total assets $ 145,899 $ 145,008 $ — $ 891 Purchase consideration payable $ 4,974 $ — $ — $ 4,974 Total liabilities $ 4,974 $ — $ — $ 4,974 Description December 31, 2015 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash and cash equivalents $ 346,266 $ 346,266 $ — $ — Available-for-sale securities 5,941 4,843 1,098 Total assets $ 352,207 $ 351,109 $ — $ 1,098 Purchase consideration payable $ 4,967 $ — $ — $ 4,967 Total liabilities $ 4,967 $ — $ — $ 4,967

Stock Based Compensation (Table

Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan	The Company uses the single-award method for allocating compensation cost related to stock options to each period. The following table sets forth the components of the Company’s share based compensation expense for the three month periods ended March 31, 2016 and 2015 (in thousands): Three months ended March 31, 2016 2015 Stock options and employee stock purchase plan $ 2,049 $ 2,252 Restricted stock units 872 722 Total stock-based compensation expense $ 2,921 $ 2,974
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The weighted-average assumptions used in estimating the grant date fair value of the stock options granted under the 2014 Plan during the three month periods ended March 31, 2016 , and 2015 , respectively along with the weighted-average grant date fair values, are set forth in the table below. Three Months Ended March 31, 2016 2015 Expected volatility 47% 42% Expected life (in years) 4.75 4.75 Risk-free interest rate 1.26% 1.56% Dividend yield — — Fair value per stock option $ 9.95 $ 18.21 Forfeiture rate 8% 8%
Schedule of Share-based Compensation, Activity	The table below sets forth a summary of activity within the 2014 and 2003 Plans for the three months ended March 31, 2016 : Number of Options (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (in thousands) (1) Outstanding at December 31, 2015 4,757 $ 20.33 3.41 $ 80,868 Granted 911 24.14 Exercised — — Forfeited (77 ) 27.69 Outstanding at March 31, 2016 5,591 $ 20.83 3.78 $ 116,467 Exercisable at March 31, 2016 2,591 $ 12.31 1.39 $ 31,879 (1) May include value from potentially anti-dilutive options whose exercise price exceeds the closing stock price.
Schedule of Nonvested Restricted Stock Units Activity	The following is a summary of non-vested restricted stock activity: Number of Units (in thousands) Weighted Average Grant Date Fair Value Non-vested at December 31, 2015 253 $ 35.31 Granted — — Forfeited — $ — Vested (34) $ 36.47 Non-vested at March 31, 2016 219 $ 35.13

Accounts Receivable Allowances

Accounts Receivable Allowances (Tables)	3 Months Ended
	Mar. 31, 2016
Receivables [Abstract]
Summary of net trade accounts receivable	Net trade accounts receivable consists of the following (in thousands): March 31, December 31, Gross accounts receivable $ 472,665 $ 466,570 Less reserves for: Chargebacks and rebates (238,028 ) (254,440 ) Product returns (49,337 ) (48,333 ) Discounts and allowances (10,281 ) (10,079 ) Advertising and promotions (1,488 ) (1,518 ) Doubtful accounts (1,348 ) (1,579 ) Trade accounts receivable, net $ 172,183 $ 150,621
Schedule of adjustments to gross sales	For the three month periods ended March 31, 2016 and 2015 , the Company recorded the following adjustments to gross sales (in thousands): Three Months Ended March 31, 2016 2015 Gross sales $ 593,392 $ 568,016 Less adjustments for: Chargebacks and rebates (293,434 ) (293,181 ) Product returns (4,286 ) (5,574 ) Discounts and allowances (11,954 ) (14,044 ) Administrative fees (14,290 ) (26,123 ) Advertising, promotions and others (1,081 ) (1,716 ) Revenues, net $ 268,347 $ 227,378

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
Components of inventory	The components of inventories are as follows (in thousands): March 31, December 31, Finished goods $ 82,021 $ 76,512 Work in process 9,900 8,905 Raw materials and supplies 98,948 99,899 Inventories, net $ 190,869 $ 185,316

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property, plant and equipment	Property, plant and equipment consist of the following (in thousands): March 31, December 31, Land and land improvements $ 17,661 $ 17,409 Buildings and leasehold improvements 86,780 85,767 Furniture and equipment 146,653 142,885 Sub-total 251,094 246,061 Accumulated depreciation (93,139 ) (87,086 ) Property, plant and equipment placed in service, net $ 157,955 $ 158,975 Construction in progress 28,303 20,639 Property, plant and equipment, net $ 186,258 $ 179,614

Goodwill and Other Intangible30

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	The following table provides a summary of the activity in goodwill by segment for the three months ended March 31, 2016 (in thousands): Consumer Health Prescription Pharmaceuticals Total Balances at December 31, 2015 $ 16,717 $ 267,993 $ 284,710 Currency translation adjustments — 6 6 Acquisitions — — — Impairments — — — Dispositions — — — Balances at March 31, 2016 $ 16,717 $ 267,999 $ 284,716
Schedule of other intangible assets	The following table sets forth information about the net book value of the Company’s other intangible assets as of March 31, 2016 and December 31, 2015, and the weighted average remaining amortization period as of March 31, 2016 and December 31, 2015 (dollar amounts in thousands): Gross Amount Accumulated Amortization Reclass-ifications Impairment Net Balance Wtd Avg Remaining Amortization Period (years) March 31, 2016 Product licensing rights $ 787,269 $ (148,211 ) $ — $ (200 ) $ 638,858 10.8 IPR&D 186,932 — — — 186,932 N/A - Indefinite lived Trademarks 16,000 (3,298 ) — — 12,702 18.1 Customer relationships 6,343 (3,721 ) — — 2,622 10.1 Other intangibles 11,235 (3,038 ) — — 8,197 6.4 Non-compete agreement 2,319 (2,319 ) — — — — $ 1,010,098 $ (160,587 ) $ — $ (200 ) $ 849,311 December 31, 2015 Product licensing rights $ 782,269 $ (132,642 ) $ 38,000 $ (34,000 ) $ 653,627 13.2 IPR&D 227,559 — (38,000 ) (2,627 ) 186,932 N/A - Indefinite lived Trademarks 16,000 (2,982 ) — — 13,018 21.8 Customer relationships 6,493 (3,716 ) — — 2,777 11.7 Other intangibles 11,235 (2,600 ) — — 8,635 7.9 Non-compete agreement 2,167 (2,167 ) — — — — $ 1,045,723 $ (144,107 ) $ — $ (36,627 ) $ 864,989

(Tables)

(Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Schedule of Variable Interest Rates	As of the date of the filing of this Form 10-Q until the maturity of the incremental term loan, our spread will be based upon the Ratings Level applicable on such date as documented below. Ratings Level Index Ratings (Moody’s/S&P) Eurodollar Spread ABR Spread Level I B1/B+ or higher 4.25% 3.25% Level II B2/B 4.75% 3.75% Level III B3/B- or lower 5.50% 4.50% As of the date of the filing of this Form 10-Q until the maturity of the existing term loan, our spread will be based upon the Ratings Level applicable on such date as documented below. Ratings Level Index Ratings (Moody’s/S&P) Eurodollar Spread ABR Spread Level I B1/B+ or higher 4.25% 3.25% Level II B2/B 4.75% 3.75% Level III B3/B- or lower 5.50% 4.50%
Schedule of Guarantor Obligations	Unless cash dominion is exercised by the lenders in connection with the JPM Revolving Facility, the Company will be required to repay the JPM Revolving Facility upon its expiration five years from issuance, subject to permitted extension, and will pay interest on the outstanding balance monthly based, at the Company’s election, on an adjusted prime/federal funds rate (“ABR”) or an adjusted LIBOR (“Eurodollar”), plus a margin determined in accordance with the Company’s consolidated fixed charge coverage ratio (EBITDA to fixed charges) as follows: Fixed Charge Coverage Ratio Revolver ABR Spread Revolver Eurodollar Spread Category 1 > 1.50 to 1.0 0.50% 1.50% Category 2 > 1.25 to 1.00 but < 1.50 to 1.00 0.75% 1.75% Category 3 < 1.25 to 1.00 1.00% 2.00%
Carrying Amount of Liability Component and Remaining Unamortized Debt Discount	At dates indicated, the net carrying amount of the liability component and the remaining unamortized debt discount were as follows (in thousands): March 31, 2016 December 31, 2015 Carrying amount of equity component $ 7,372 $ 7,372 Carrying amount of the liability component 42,912 42,465 Unamortized discount of the liability component 303 750 Unamortized deferred financing costs 55 136
Expenses in Relation to Convertible Notes	During the three month periods ended March 31, 2016 and 2015, the Company recorded the following expenses in relation to the Notes (in thousands): Three months ended March 31, 2016 2015 Expense Description Interest expense at 3.5% coupon rate (1) $ 432 $ 759 Debt discount amortization 447 835 Amortization of deferred financing costs 81 151 Loss on Conversion — 73 $ 960 $ 1,818 (1) As a result of the restatement of the 2014 financial data and the resultant delays in filings of the 2015 financial statements the Company had been required to remit an additional 0.5% interest penalty to all holders of the convertible notes throughout the three month period ended March 31, 2016.
Schedule of Maturities of Long-term Debt	Aggregate cumulative maturities of long-term obligations (including the incremental and existing term loans, convertible debt and the JPM revolver) as of March 31, 2016 are: (In thousands) 2016 2017 2018 2019 Thereafter Maturities $ 43,215 $ — $ — $ — $ 831,938

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	A reconciliation of the earnings per share data from a basic to a fully diluted basis is detailed below (amounts in thousands, except per share data): Three Months Ended March 31, 2016 2015 Net income $ 41,886 $ 37,538 Convertible debt income adjustments, net of tax 604 1,107 Net income adjusted for convertible debt as used for diluted earnings per share $ 42,490 $ 38,645 Net income per share: Basic $ 0.35 $ 0.33 Diluted (1) $ 0.34 $ 0.31 Shares used in computing net income per share: Weighted average basic shares outstanding 119,516 113,352 Dilutive securities: Stock option and unvested RSAs 1,172 2,085 Shares issuable upon conversion of the notes 4,933 9,940 Total dilutive securities 6,105 12,025 Weighted average diluted shares outstanding 125,621 125,377 Shares subject to stock options omitted from the calculation of income per share as their effect would have been anti-dilutive 2,430 575 (1) Due to a change in the expectation that management may settle all future note conversions solely through shares in the year and quarter ended December 31, 2014, the diluted income from continuing operations per share calculation includes the dilutive effect of convertible debt and is offset by the exclusion of interest expense and deferred financing fees related to the convertible debt of $0.6 million and $1.1 million , after-tax for the three month periods ended March 31, 2016 and 2015, respectively.

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Selected financial info by reportable segment	Selected financial info by reportable segment is presented below (in thousands). Three Months Ended March 31, 2016 2015 Revenues: Prescription Pharmaceuticals $ 250,749 $ 210,554 Consumer Health 17,598 16,824 Total revenues 268,347 227,378 Gross Profit: Prescription Pharmaceuticals 154,635 121,159 Consumer Health 8,382 9,004 Total gross profit 163,017 130,163 Operating expenses 75,438 56,896 Operating income 87,579 73,267 Other expense (21,007 ) (14,939 ) Income before income taxes $ 66,572 $ 58,328

Business Combinations, Dispos34

Business Combinations, Dispositions and Other Strategic Investments (Tables)	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table sets forth the consideration paid for the Akorn AG Acquisition and the fair values of the acquired assets and assumed liabilities (in millions of USD) as of the acquisition date adjusted in accordance with GAAP. The figures below may differ from historical financial results of Akorn AG. Consideration: Amount of cash paid $ 25.9 Outstanding amount payable to Fareva 2.5 Total consideration at closing $ 28.4 Recognized amounts of identifiable assets acquired: Cash and cash equivalents $ 1.2 Accounts receivable 3.4 Inventory 4.2 Other current assets 0.9 Property and equipment 26.6 Total assets acquired 36.3 Assumed current liabilities (1.7 ) Assumed non-current liabilities (3.9 ) Deferred tax liabilities (1.4 ) Total liabilities assumed (7.0 ) Bargain purchase gain (0.9 ) Fair value of assets acquired $ 28.4

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitment Payment to Strategic Business Partners	The table below summarizes contingent potential milestone payments due to strategic partners in the years 2016 and beyond, assuming all such contingencies occur (in thousands): Year ending December 31, Amount 2016 $ 13,153 2017 4,418 2018 1,771 2019 and Beyond — Total $ 19,342

Customer and Supplier Concent36

Customer and Supplier Concentration (Tables)	3 Months Ended
	Mar. 31, 2016
Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Schedules of Concentration of Risk, by Risk Factor	The following table sets forth the percentage of the Company’s gross and net sales for the three month periods ended March 31, 2016 and 2015, and gross accounts receivable as of March 31, 2016 and December 31, 2015, attributable to the Big 3 Wholesalers: Three months ended March 31, Big 3 Wholesalers combined : 2016 2015 Percentage of gross sales 79% 76% Percentage of net sales revenues 67% 67%
Accounts Receivable [Member]
Concentration Risk [Line Items]
Schedules of Concentration of Risk, by Risk Factor	March 31, 2016 December 31, 2015 Percentage of gross trade accounts receivable 79% 83%

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Information about the Company's Income Tax Provision	The following table sets forth information about the Company’s income tax provision for the periods indicated (dollar amounts in thousands): Three Months ended March 31, 2016 2015 Income before income taxes $ 66,572 $ 58,328 Income tax provision 24,686 20,790 Net income $ 41,886 $ 37,538 Income tax provision/benefit as a percentage of income before income taxes 37.1 % 35.6 %

Summary of Significant Accoun38

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Oct. 24, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	$ 4,901	$ 5,941
Unrealized Gain (Loss) on Securities	1,700
Available for Sale Securities Sold		$ 2,600	$ 600
Nicox [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Original cost basis				$ 10,800
Aciex Therapeutics Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	4,900
Marketable Securities, Unrealized Gain (Loss)	(2,700)
Initial Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	$ 12,500
Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Intangible asset useful life (in years)	1 year
Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Intangible asset useful life (in years)	30 years

Summary of Significant Accoun39

Summary of Significant Accounting Policies (Details) - Fair Values of the Companys Financial Instruments - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 140,998	$ 346,266
Available-for-sale securities	4,901	5,941
Total assets	145,899	352,207
Purchase consideration payable	4,974	4,967
Total liabilities	4,974	4,967
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	140,998	346,266
Available-for-sale securities	4,010	4,843
Total assets	145,008	351,109
Purchase consideration payable	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	$ 0
Available-for-sale securities	0
Total assets	0	$ 0
Purchase consideration payable	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Available-for-sale securities	891	1,098
Total assets	891	1,098
Purchase consideration payable	4,974	4,967
Total liabilities	$ 4,974	$ 4,967

Stock Based Compensation (Detai

Stock Based Compensation (Details) - USD ($) $ in Millions	Sep. 05, 2014	May. 02, 2014	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from stock options exercised (in Dollars)				$ 9.2
2014 and 2003 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of stock options (in Shares)			0
2003 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of stock options (in Shares)				2,200,000
Tax benefit from compensation expense (in Dollars)				$ 84.9
Restricted stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares granted (in Shares)			0
Restricted stock [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares granted (in Shares)	8,034	71,582
Annual vesting percentage	25.00%	25.00%
Restricted stock [Member] | Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual vesting percentage		25.00%
Number of modified options (in Shares)		2,300,000
Restricted stock [Member] | Senior Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares granted (in Shares)	257,416
Annual vesting percentage	25.00%
2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance (in Shares)		7,500,000

Stock Based Compensation (Det41

Stock Based Compensation (Details) - Allocated Share-based Compensation Expense - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 2,921	$ 2,974
Stock options and employee stock purchase plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2,049	2,252
Restricted stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 872	$ 722

Stock Based Compensation (Det42

Stock Based Compensation (Details) - Weighted-average Assumptions for Stock Options - 2014 Plan [Member] - $ / shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility (as a percent)	47.00%	42.00%
Expected life (in years)	4 years 9 months	4 years 9 months
Risk-free interest rate (as a percent)	1.26%	1.56%
Dividend yield (as a percent)	0.00%	0.00%
Fair value per stock option (in Dollars per share)	$ 9.95	$ 18.21
Forfeiture rate (as a percent)	8.00%	8.00%

Stock Based Compensation (Det43

Stock Based Compensation (Details) - Stock Option Activity - 2014 and 2003 Stock Option Plan [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Number of Options (in thousands)
Options outstanding, beginning balance (in Shares)	4,757,000
Granted (in Shares)	911,000
Exercised (in Shares)	0
Forfeited (in Shares)	(77,000)
Options outstanding, ending balance (in Shares)	5,591,000	4,757,000
Options, exercisable (in Shares)	2,591,000
Weighted Average Exercise Price
Weighted average exercise price, beginning balance (in Dollars per share)	$ 20.33
Granted (in Dollars per share)	24.14
Exercised (in Dollars per share)	0
Forfeited (in Dollars per share)	27.69
Weighted average exercise price, ending balance (in Dollars per share)	20.83	$ 20.33
Weighted average exercise price, exercisable (in Dollars per share)	$ 12.31
Weighted Average Remaining Contractual Term (Years)	3 years 9 months 11 days	3 years 4 months 28 days
Weighted Average Remaining Contractual Term, exercisable (Years)	1 year 4 months 21 days
Aggregate Intrinsic Value (in thousands)	$ 116,467	$ 80,868
Aggregate Intrinsic Value, exercisable (in thousands)	$ 31,879

Stock Based Compensation (Det44

Stock Based Compensation (Details) - Non-vested Restricted Stock Activity - Restricted stock [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Number of Units (in thousands)
Non-vested shares, beginning balance (in Shares) | shares	253
Granted (in Shares) | shares	0
Forfeited (in Shares) | shares	0
Vested (in Shares) | shares	(34)
Non-vested shares, ending balance (in Shares) | shares	219
Weighted Average Grant Date Fair Value
Weighted average grant date fair value, beginning balance (in Dollars per share) | $ / shares	$ 35.31
Granted (in Dollars per share) | $ / shares	0
Forfeited (in Dollars per share) | $ / shares	0
Vested (in Dollars per share) | $ / shares	36.47
Weighted average grant date fair value, ending balance (in Dollars per share) | $ / shares	$ 35.13

Accounts Receivable Allowance45

Accounts Receivable Allowances (Details) - Net Trade Accounts Receivable - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Receivables [Abstract]
Gross accounts receivable	$ 472,665	$ 466,570
Less reserves for:
Chargebacks and rebates	(238,028)	(254,440)
Product returns	(49,337)	(48,333)
Discounts and allowances	(10,281)	(10,079)
Advertising and promotions	(1,488)	(1,518)
Doubtful accounts	(1,348)	(1,579)
Trade accounts receivable, net	$ 172,183	$ 150,621

Accounts Receivable Allowance46

Accounts Receivable Allowances (Details) - Summary of Adjustments to Gross Sales - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Receivables [Abstract]
Gross sales	$ 593,392	$ 568,016
Less adjustments for:
Chargebacks and rebates	(293,434)	(293,181)
Product returns	(4,286)	(5,574)
Discounts and allowances	(11,954)	(14,044)
Administrative fees	(14,290)	(26,123)
Advertising, promotions and others	(1,081)	(1,716)
Revenues, net	$ 268,347	$ 227,378

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory valuation reserves	$ 23.2	$ 21.5

Inventories (Details) - Compone

Inventories (Details) - Components of Inventories - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Finished goods	$ 82,021	$ 76,512
Work in process	9,900	8,905
Raw materials and supplies	98,948	99,899
Inventories, net	$ 190,869	$ 185,316

Property, Plant and Equipment49

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 186,258		$ 179,614
Depreciation expense	6,000	$ 5,000
India and Switzerland [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 56,700		$ 52,600

Property, Plant and Equipment50

Property, Plant and Equipment (Details) - Property, Plant, and Equipment - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	$ 251,094	$ 246,061
Accumulated depreciation	(93,139)	(87,086)
Property, plant and equipment, net	186,258	179,614
Land and land improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	17,661	17,409
Building and Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	86,780	85,767
Furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	146,653	142,885
Property, plant and equipment placed in service, net [Member]
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	157,955	158,975
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	$ 28,303	$ 20,639

Goodwill and Other Intangible51

Goodwill and Other Intangible Assets (Details) - Summary of Goodwill $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Goodwill [Roll Forward]
Balances at December 31, 2015	$ 284,710
Currency translation adjustments	6
Acquisitions	0
Impairments	0
Dispositions	0
Balances at March 31, 2016	284,716
Consumer Health [Member]
Goodwill [Roll Forward]
Balances at December 31, 2015	16,717
Currency translation adjustments	0
Acquisitions	0
Impairments	0
Dispositions	0
Balances at March 31, 2016	16,717
Prescription Pharmaceuticals [Member]
Goodwill [Roll Forward]
Balances at December 31, 2015	267,993
Currency translation adjustments	6
Acquisitions	0
Impairments	0
Dispositions	0
Balances at March 31, 2016	$ 267,999

Goodwill and Other Intangible52

Goodwill and Other Intangible Assets (Details) - Intangible Assets - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$ (160,587)		$ (144,107)
Intangible Assets, Gross Amount	1,010,098		1,045,723
Impairment	(200)		(36,627)
Intangible Assets, Net Balance	849,311		864,989
Intangible assets amortization expense	16,518	$ 16,377
IPR&D [Member]
Indefinite-lived Intangible Assets [Line Items]
Gross Amount	186,932		227,559
Reclassifications	0		(38,000)
Impairment	0		(2,627)
Net Balance	186,932		186,932
Product licensing rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	787,269		782,269
Accumulated Amortization	(148,211)		(132,642)
Reclassifications	0		38,000
Impairment	(200)		(34,000)
Net Balance	$ 638,858		$ 653,627
Wgtd Avg Remaining Amortization Period (years)	10 years 9 months		13 years 2 months 12 days
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 16,000		$ 16,000
Accumulated Amortization	(3,298)		(2,982)
Reclassifications	0		0
Impairment	0		0
Net Balance	$ 12,702		$ 13,018
Wgtd Avg Remaining Amortization Period (years)	18 years 1 month 13 days		21 years 9 months 18 days
Customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 6,343		$ 6,493
Accumulated Amortization	(3,721)		(3,716)
Reclassifications	0		0
Impairment	0		0
Net Balance	$ 2,622		$ 2,777
Wgtd Avg Remaining Amortization Period (years)	10 years 29 days		11 years 8 months 12 days
Other intangibles [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 11,235		$ 11,235
Accumulated Amortization	(3,038)		(2,600)
Reclassifications	0		0
Impairment	0		0
Net Balance	$ 8,197		$ 8,635
Wgtd Avg Remaining Amortization Period (years)	6 years 5 months 9 days		7 years 10 months 24 days
Non-compete agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 2,319		$ 2,167
Accumulated Amortization	(2,319)		(2,167)
Reclassifications	0		0
Impairment	0		0
Net Balance	$ 0		$ 0
Wgtd Avg Remaining Amortization Period (years)	0 years		0 years

Financing Arrangements (Details

Financing Arrangements (Details)	Feb. 16, 2016USD ($)	Aug. 12, 2014USD ($)	Jun. 01, 2011USD ($)	Apr. 17, 2014USD ($)	Jun. 30, 2011USD ($)$ / shares	Mar. 31, 2016USD ($)dayletter_of_credit$ / shares	Mar. 31, 2015USD ($)	Mar. 31, 2012USD ($)day$ / shares	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2015USD ($)
Debt Instrument [Line Items]
Amortization of deferred financing costs						$ (6,311,000)	$ (996,000)
JPM Revolving Facility [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Debt term				5 years
Annual increase in interest rate in an event of default				2.00%
Commitment fee, minimum percentage of commitments				12.50%
Commitment fee, minimum amount of commitments				$ 15,000,000
Commitment fee, number of consecutive days for commitments				30 days
Debt Instrument, Covenant, Minimum Liquidity				$ 120,000,000
Debt Instrument, Covenant, Minimum Liquidity, Additional Percentage of Commitments				25.00%
Debt Instrument, Covenant, Minimum EBITDA to Fixed Charges Ratio				1
Debt Instrument, Covenant, Minimum EBITDA to Fixed Charges Ratio, Measurment Duration				12 months
Unused line fee as a percentage				0.25%
Senior Notes [Member] | Notes [Member]
Debt Instrument [Line Items]
Face amount of debt						$ 43,215,000
Convertible Notes Payable					$ 120,000,000
Stated interest rate					3.50%
Deferred financing costs			$ 4,700,000
Proceeds from Convertible Debt					$ 115,300,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares					$ 8.76
Debt Instrument, Convertible, Conversion Ratio						0.1142
Share Price (in Dollars per share) | $ / shares						$ 23.53
Debt Instrument, Convertible, Pro Forma Conversion Value						$ 116,100,000
Debt Instrument, Convertible, Threshold Trading Days | day								20
Debt Instrument, Convertible, Threshold Consecutive Trading Days						30 days		30 days
Debt Conversion, Converted Instrument, Additional Amount									$ 1,200,000	$ 1,000,000
Debt Conversion, Original Debt, Amount						$ 0			44,300,000	$ 32,500,000	$ 76,800,000
Debt Instrument, Convertible, Stock Price Trigger (in Dollars per share) | $ / shares								$ 11.39
Debt Instrument, Convertible, If-converted Value in Excess of Principal								$ 20,500,000
Senior Notes [Member] | Notes [Member] | Over-Allotment Option [Member]
Debt Instrument [Line Items]
Convertible Notes Payable					$ 20,000,000
Senior Notes [Member] | Notes [Member] | Long-term Debt [Member]
Debt Instrument [Line Items]
Deferred financing costs			3,900,000
Senior Notes [Member] | Notes [Member] | Additional Paid-in Capital [Member]
Debt Instrument [Line Items]
Deferred financing costs			800,000
Convertible Debt [Member]
Debt Instrument [Line Items]
Unamortized deferred financing costs						55,000			136,000		136,000
Amortization of deferred financing costs						(81,000)	(151,000)
Debt interest expense						$ 960,000	$ 1,818,000
Stated interest rate						3.50%	3.50%
Deferred financing costs			21,300,000
Additional interest penalty for convertible notes (as a percent)						0.50%
Deferred tax liability for debt discount			8,600,000
Reduction in valuation allowance			$ 8,600,000
Potential [Member] | JPM Revolving Facility [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 200,000,000
Scenario #1 [Member] | Senior Notes [Member] | Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Threshold Trading Days | day						20
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger						130.00%
Scenario #2 [Member] | Senior Notes [Member] | Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Threshold Consecutive Trading Days						5 days
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger						98.00%
Scenario #2 [Member] | Senior Notes [Member] | Notes [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Threshold Consecutive Trading Days						5 days
Incremental Term Loan Facility [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 445,000,000
Incremental Term Loan Agreement [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Periodic payment as a percent of the initial loan amount				0.25%
Face amount of debt				$ 445,000,000
Debt term		7 years
Voluntary prepayment of all future quarterly principal payments	$ (85,200,000)
Amount outstanding						$ 354,300,000
Potential reduction in basis spread on variable rate		0.25%
Potential reduction in basis spread on variable rate, senior debt to EBITDA ratio		2.25
Annual increase in interest rate in an event of default		2.00%
Unamortized deferred financing costs						9,600,000			10,700,000		10,700,000
Additional financing costs related to continued restatement of loans						1,500,000
Amortization of deferred financing costs						(2,600,000)	$ (300,000)
Debt interest expense						4,600,000	5,000,000
Incremental Term Loan Agreement [Member] | Prime Rate [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Basis spread on variable rate		2.50%
Incremental Term Loan Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Basis spread on variable rate		3.50%
Minimum effective interest rate		4.50%
Term Loan Facility [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 600,000,000
Periodic payment as a percent of the initial loan amount					0.25%
Face amount of debt					$ 600,000,000
Debt term				7 years
Voluntary prepayment of all future quarterly principal payments	$ (114,800,000)
Amount outstanding						477,700,000
Potential reduction in basis spread on variable rate				0.25%
Annual increase in interest rate in an event of default				2.00%
Unamortized deferred financing costs						14,600,000			$ 16,100,000		$ 16,100,000
Additional financing costs related to continued restatement of loans						2,100,000
Potential increase in maximum borrowing capacity				$ 150,000,000
Debt Instrument, Periodic Payment, Percent of Initial Loan Amount					0.25%
Amortization of deferred financing costs						(3,500,000)	(500,000)
Debt interest expense						6,200,000	$ 6,700,000
Term Loan Facility [Member] | Maximum [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Potential reduction in basis spread on variable rate, senior debt to EBITDA ratio				2.25
Term Loan Facility [Member] | Base Rate [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Basis spread on variable rate				2.50%
Term Loan Facility [Member] | Eurodollar [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Basis spread on variable rate				3.50%
Minimum effective interest rate				4.50%
JPM Revolving Facility [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity						$ 148,500,000
JPM Revolving Facility [Member] | JPM Revolving Facility [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 150,000,000
JPM Revolving Facility [Member] | Letter of Credit [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Letters of Credit Outstanding, Number | letter_of_credit						1
Letters of Credit Outstanding, Amount						$ 1,500,000
Revolving Credit Facility [Member] | JPM Revolving Facility [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Borrowing base, percent of eligible accounts receivable				85.00%
Revolving Credit Facility [Member] | The Lesser Of For Scenario Two Consideration A [Member] | JPM Revolving Facility [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Borrowing base, percent of materials and WIP on FIFO				65.00%
Revolving Credit Facility [Member] | The Lesser Of For Scenario Two Consideration B [Member] | JPM Revolving Facility [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Borrowing base, percent of liquidation value				85.00%
Revolving Credit Facility [Member] | The Lesser Of For Scenario Three Consideration A [Member] | JPM Revolving Facility [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Borrowing base, percent finished goods				75.00%
Revolving Credit Facility [Member] | The Lesser Of For Scenario Three Consideration B [Member] | JPM Revolving Facility [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Borrowing base, percent of liquidation of finished goods				85.00%
Borrowing base, percent of eligible inventory liquidation value				85.00%
Borrowing base, percent of market value finished goods				75.00%
Letter of Credit [Member] | JPM Revolving Facility [Member] | JP Morgan [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 10,000,000

Financing Arrangements (Detai54

Financing Arrangements (Details) - Variable Interest Rates - JP Morgan [Member]	3 Months Ended
	Mar. 31, 2016
Incremental Term Loan Facility [Member] | Eurodollar Spread [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	5.00%
Incremental Term Loan Facility [Member] | Eurodollar Spread [Member] | Moody's, B1 Rating [Member] | Standard & Poor's, B Plus Rating or higher [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	4.25%
Incremental Term Loan Facility [Member] | Eurodollar Spread [Member] | Moody's, B2 Rating [Member] | Standard & Poor's, B Rating [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	4.75%
Incremental Term Loan Facility [Member] | Eurodollar Spread [Member] | Moody's, B3 Rating [Member] | Standard & Poor's, B Minus or lower Rating [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	5.50%
Incremental Term Loan Facility [Member] | ABR Spread [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	4.00%
Incremental Term Loan Facility [Member] | ABR Spread [Member] | Moody's, B1 Rating [Member] | Standard & Poor's, B Plus Rating or higher [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	3.25%
Incremental Term Loan Facility [Member] | ABR Spread [Member] | Moody's, B2 Rating [Member] | Standard & Poor's, B Rating [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	3.75%
Incremental Term Loan Facility [Member] | ABR Spread [Member] | Moody's, B3 Rating [Member] | Standard & Poor's, B Minus or lower Rating [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	4.50%
Existing Term Loan Facility [Member] | Eurodollar Spread [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	5.00%
Existing Term Loan Facility [Member] | Eurodollar Spread [Member] | Moody's, B1 Rating [Member] | Standard & Poor's, B Plus Rating or higher [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	4.25%
Existing Term Loan Facility [Member] | Eurodollar Spread [Member] | Moody's, B2 Rating [Member] | Standard & Poor's, B Rating [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	4.75%
Existing Term Loan Facility [Member] | Eurodollar Spread [Member] | Moody's, B3 Rating [Member] | Standard & Poor's, B Minus or lower Rating [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	5.50%
Existing Term Loan Facility [Member] | ABR Spread [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	4.00%
Existing Term Loan Facility [Member] | ABR Spread [Member] | Moody's, B1 Rating [Member] | Standard & Poor's, B Plus Rating or higher [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	3.25%
Existing Term Loan Facility [Member] | ABR Spread [Member] | Moody's, B2 Rating [Member] | Standard & Poor's, B Rating [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	3.75%
Existing Term Loan Facility [Member] | ABR Spread [Member] | Moody's, B3 Rating [Member] | Standard & Poor's, B Minus or lower Rating [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	4.50%

Financing Arrangements (Detai55

Financing Arrangements (Details) - JPM Revolving Facility, Interest Terms	1 Months Ended
	Apr. 17, 2014
Category 1 [Member] | Base Rate [Member]
Guarantor Obligations [Line Items]
Basis spread on variable rate	0.50%
Category 1 [Member] | Base Rate [Member] | Minimum [Member]
Guarantor Obligations [Line Items]
Fixed charge coverage ratio	1.50
Category 1 [Member] | Eurodollar [Member]
Guarantor Obligations [Line Items]
Basis spread on variable rate	1.50%
Category 1 [Member] | Eurodollar [Member] | Minimum [Member]
Guarantor Obligations [Line Items]
Fixed charge coverage ratio	1.50
Category 2 [Member] | Base Rate [Member]
Guarantor Obligations [Line Items]
Basis spread on variable rate	0.75%
Category 2 [Member] | Base Rate [Member] | Minimum [Member]
Guarantor Obligations [Line Items]
Fixed charge coverage ratio	1.25
Category 2 [Member] | Base Rate [Member] | Maximum [Member]
Guarantor Obligations [Line Items]
Fixed charge coverage ratio	1.50
Category 2 [Member] | Eurodollar [Member]
Guarantor Obligations [Line Items]
Basis spread on variable rate	1.75%
Category 2 [Member] | Eurodollar [Member] | Minimum [Member]
Guarantor Obligations [Line Items]
Fixed charge coverage ratio	1.25
Category 2 [Member] | Eurodollar [Member] | Maximum [Member]
Guarantor Obligations [Line Items]
Fixed charge coverage ratio	1.50
Category 3 [Member] | Base Rate [Member]
Guarantor Obligations [Line Items]
Basis spread on variable rate	1.00%
Category 3 [Member] | Base Rate [Member] | Maximum [Member]
Guarantor Obligations [Line Items]
Fixed charge coverage ratio	1.25
Category 3 [Member] | Eurodollar [Member]
Guarantor Obligations [Line Items]
Basis spread on variable rate	2.00%
Category 3 [Member] | Eurodollar [Member] | Maximum [Member]
Guarantor Obligations [Line Items]
Fixed charge coverage ratio	1.25

Financing Arrangements (Detai56

Financing Arrangements (Details) - Net Carrying Amount of the Liability Component and the Remaining Unamortized Debt Discount - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Carrying amount of the liability component	$ 807,142	$ 994,033
Convertible Debt [Member]
Debt Instrument [Line Items]
Carrying amount of equity component	7,372	7,372
Carrying amount of the liability component	42,912	42,465
Unamortized discount of the liability component	303	750
Unamortized deferred financing costs	$ 55	$ 136

Financing Arrangements (Detai57

Financing Arrangements (Details) - Expenses in Relation to Convertible Notes - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument [Line Items]
Amortization of deferred financing costs	$ 6,311	$ 996
Convertible Debt [Member]
Debt Instrument [Line Items]
Interest expense at 3.5% coupon rate	432	759
Debt discount amortization	447	835
Amortization of deferred financing costs	81	151
Loss on Conversion	0	73
Debt interest expense	$ 960	$ 1,818
Coupon rate	3.50%	3.50%

Financing Arrangements (Detai58

Financing Arrangements (Details) - Maturities of Long-Term Obligations $ in Thousands	Mar. 31, 2016USD ($)
Maturities of Long-term Obligations
2,016	$ 43,215
2,017	0
2,018	0
2,019	0
Thereafter	$ 831,938

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Earnings Per Share [Abstract]
Net income	$ 41,886	$ 37,538
Convertible debt income adjustments, net of tax	604	1,107
Net income adjusted for convertible debt as used for diluted earnings per share	$ 42,490	$ 38,645
Net income per share:
Basic (in Dollars per share)	$ 0.35	$ 0.33
Diluted (in Dollars per share)	$ 0.34	$ 0.31
Shares used in computing net income per share:
Weighted average basic shares outstanding (in Shares)	119,516	113,352
Dilutive securities:
Stock option and unvested RSAs (in Shares)	1,172	2,085
Shares issuable upon conversion of convertible notes (in Shares)	4,933	9,940
Total dilutive securities (in Shares)	6,105	12,025
Weighted average diluted shares outstanding (in Shares)	125,621	125,377
Shares subject to stock options omitted from the calculation of income per share as their effect would have been anti-dilutive (in Shares)	2,430	575

Segment Information (Details)

Segment Information (Details)	3 Months Ended
	Mar. 31, 2016segment
Segment Reporting [Abstract]
Number of Reportable Segments (in segment)	2

Segment Information (Details) -

Segment Information (Details) - Financial Information by Segment - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Revenues	$ 268,347	$ 227,378
Gross Profit:
Gross Profit	163,017	130,163
Operating expenses	75,438	56,896
OPERATING INCOME	87,579	73,267
Other expense	(21,007)	(14,939)
INCOME BEFORE INCOME TAXES	66,572	58,328
Prescription Pharmaceuticals [Member]
Revenues:
Revenues	250,749	210,554
Gross Profit:
Gross Profit	154,635	121,159
Consumer Health [Member]
Revenues:
Revenues	17,598	16,824
Gross Profit:
Gross Profit	$ 8,382	$ 9,004

Business Combinations, Dispos62

Business Combinations, Dispositions and Other Strategic Investments (Details) $ in Thousands, shares in Millions, SFr in Millions	Jan. 02, 2015USD ($)	Jul. 22, 2014CHF (SFr)	Jun. 27, 2014USD ($)	Apr. 17, 2014USD ($)	Sep. 30, 2011USD ($)	Aug. 01, 2011USD ($)	Mar. 31, 2016USD ($)shares	Mar. 31, 2015USD ($)	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)shares	Oct. 24, 2014shares
Business Acquisition [Line Items]
Acquisition-related costs							$ 197	$ 1,257
Bargain purchase gain							0	849
Aggregate cost method investment							130		$ 129
Maximum ownership interest for cost method investment (as a Percent)			20.00%
Available-for-sale securities							$ 4,901		$ 5,941
Aciex Therapeutics Inc. [Member]
Business Acquisition [Line Items]
Shares received that were subject to certain lockup provisions (in shares) | shares											4.3
Number of shares soldl (in shares) | shares							0		1.1	0.2
Proceeds from sale of investment									$ 2,600	$ 600
Realized loss on investment									$ (200)
Unrealized holding loss on investment							$ 2,700
Available-for-sale securities							4,900
Excelvision AG [Member]
Business Acquisition [Line Items]
Consideration for share purchase agreement	$ 28,400	SFr 21.7
Amount of cash paid	25,900
Acquisition-related costs							0	100
Bargain purchase gain	$ 900
Revenue from acquiree since acquisition							$ 6,900	$ 6,500
Aciex Agreement [Member]
Business Acquisition [Line Items]
Interests acquired through Preferred Stock Purchase Agreement					$ 2,000	$ 8,000
Aggregate cost method investment			$ 10,800
Aciex Agreement [Member] | Convertible Debt [Member]
Business Acquisition [Line Items]
Cash paid for Secured Note and Warrant Purchase Agreement			$ 400	$ 400

Business Combinations, Dispos63

Business Combinations, Dispositions and Other Strategic Investments (Details) - Identifiable Assets and Liabilities Acquired $ in Thousands, SFr in Millions	Jan. 02, 2015USD ($)	Jul. 22, 2014CHF (SFr)	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)
Recognized amounts of identifiable assets acquired:
Bargain purchase gain			$ 0	$ (849)
Excelvision AG [Member]
Consideration:
Amount of cash paid	$ 25,900
Outstanding amount payable to Fareva	2,500
Total consideration at closing	28,400	SFr 21.7
Recognized amounts of identifiable assets acquired:
Cash and cash equivalents	1,200
Accounts receivable	3,400
Inventory	4,200
Other current assets	900
Property and equipment	26,600
Total assets acquired	36,300
Assumed current liabilities	(1,700)
Assumed non-current liabilities	(3,900)
Deferred tax liabilities	(1,400)
Total liabilities assumed	(7,000)
Bargain purchase gain	(900)
Fair value of assets acquired	$ 28,400

Commitments and Contingencies64

Commitments and Contingencies (Details) - Commitment Payment to Strategic Business Partners - USD ($) $ in Thousands	Sep. 12, 2012	Aug. 31, 2014	Mar. 31, 2016
Contingent Potential Milestone Payments, Year ending December 31,
2,016			$ 13,153
2,017			4,418
2,018			1,771
2019 and Beyond			0
Total			$ 19,342
Pending Litigation [Member] | Fera Pharmaceuticals, LLC v. Akorn Inc. [Member]
Loss Contingencies [Line Items]
Damages sought	$ 135,000
Threatened Litigation [Member]
Loss Contingencies [Line Items]
Damages sought		$ 5,200

Customer and Supplier Concent65

Customer and Supplier Concentration (Details)	3 Months Ended
	Mar. 31, 2016customer	Mar. 31, 2016productcustomer	Mar. 31, 2016customersupplier	Mar. 31, 2015productsupplier
Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Number of significant customers (in customer) | customer	3	3	3
Supplier Concentration Risk [Member]
Concentration Risk [Line Items]
Number of significant suppliers (in supplier)	0		0	0
Product Concentration Risk [Member]
Concentration Risk [Line Items]
Number of significant products (in product)		0		0
Product Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Number of significant products (in product)		1		1
Concentration risk percentage	18.00%			10.00%

Customer and Supplier Concent66

Customer and Supplier Concentration (Details) - Concentration Risk for the Company's Gross and Net Sales - Big 3 Wholesalers [Member] - Customer Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Percentage of gross sales [Member]
Concentration Risk [Line Items]
Concentration risk percentage	79.00%	76.00%
Percentage of net sales revenue [Member]
Concentration Risk [Line Items]
Concentration risk percentage	67.00%	67.00%

Customer and Supplier Concent67

Customer and Supplier Concentration (Details) - Concentration Risk for the Company's Receivables	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Big 3 Wholesalers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Percentage of gross trade accounts receivable	79.00%	83.00%

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit) (in Dollars)	$ 24,686	$ 20,790
Income Tax Disclosure [Line Items]
Effective Income Tax Rate Reconciliation (as a Percent)	37.10%	35.60%
Unrecognized Tax Benefits (in Dollars)	$ 2,400			$ 2,300
Unrecognized tax benefits that would impact the Company's effective tax rate	1,600
Unrecognized tax benefits that would impact goodwill	$ 800
Scenario, Forecast [Member]
Income Tax Disclosure [Line Items]
Effective Income Tax Rate Reconciliation (as a Percent)			37.00%

Income Taxes (Details) - Income

Income Taxes (Details) - Income Tax Provision - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income before income taxes	$ 66,572	$ 58,328
Income tax provision	24,686	20,790
CONSOLIDATED NET INCOME	$ 41,886	$ 37,538
Income tax provision/benefit as a percentage of income/loss before income taxes	37.10%	35.60%

Related Party Transactions (Det

Related Party Transactions (Details) - Polsinelli [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Related Party Transaction [Line Items]
Legal services obtained	$ 0.3	$ 0.2
Accounts payable for legal services	$ 0.1	$ 0.1